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The aim of this research was to investigate the role of variability in antioxidant 
defenses in susceptibility to chronic obstructive pulmonary disease (COPD).  
Although exposure to cigarette smoke is the most important risk factor for COPD and 
is present in the vast majority of cases, only a minority of smokers develop disease.  
The determinants of disease susceptibility are key to understanding etiology and 
targeting interventions.  The studies conducted for this dissertation address the 
hypothesis that susceptibility results from limitations in antioxidant defenses, resulting 
from low dietary antioxidant intake or variation in genetic factors influencing 
antioxidant function, to counteract the assault of oxidants present in cigarette smoke.   
The first project addressed the association of dietary antioxidants and rate of decline in 
lung function in a prospective study of elderly.  Among current smokers, higher 
intakes of foods with antioxidant properties were each associated with an attenuated 
rate of decline in lung function, with the strongest associations observed in the 
subgroup of smokers who quit during follow-up; this study supports a role of 
antioxidant defenses in determining COPD susceptibility.  Sequence variation in genes 
encoding antioxidant-related enzymes also contributes to an individual’s antioxidant 
defenses and the second and third projects address the role of genetic variation.  Given 
that published research on the relation of candidate genes encoding antioxidant 
enzymes with lung function is rapidly emerging, a systematic review of the literature 
 was conducted.  Conclusions from this work motivated selection of candidate genes 
and study design decisions for the final project of this dissertation: an association 
study of SNPs in genes encoding antioxidant enzymes and lung function phenotypes 
in an elderly cohort.  SNPs were selected for coverage of the full sequence variation of 
a broad range of antioxidant enzymes.  SNPs in genes encoding members of the 
peroxiredoxin and isocitrate dehydrogenases were consistently associated with lung 
phenotypes, particularly in interaction with smoking parameters.  The findings are 
consistent with the hypothesis that variability in the antioxidant defenses is of 
particular relevance in those with high oxidant burden.  The results from these studies 
support the hypothesis that variability in antioxidant defenses contributes to COPD 
susceptibility.   
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 CHAPTER 1 
INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by the 
development of airflow limitation that is not fully reversible, a state that is seen in the 
progression of emphysema and chronic bronchitis.  COPD is a major cause of 
morbidity(1), with symptoms including shortness of breath, decreased exercise 
capability, wheezing, recurrent respiratory infections, severe cough, and poor overall 
oxygenation.  At advanced stages, COPD commonly progresses to respiratory failure 
and death.  COPD is the fourth leading cause of mortality in the U.S.(2), and the 
public health burden of this disease is growing(3) . 
The single most important risk factor for the development of COPD is exposure to 
cigarette smoke, with current or former smokers constituting approximately 80-90% of 
COPD patients (4, 5).  Despite the clear importance of smoking in the etiology of this 
disease, there is considerable variation among smokers in their response to cigarette 
smoke exposure.  Several large population-based studies reported that 17% of middle-
aged smokers and 43% of older current smokers had spirometry-defined COPD(6). A 
landmark study of middle-aged working men found that 12% of moderate smokers 
and 26% of heavy smokers had airflow obstruction(7).  The latter study is often cited 
in support of the susceptibility hypothesis, that a minority of smokers are vulnerable to 
the damaging effects of cigarette smoke.  A dissenting view suggests the study by 
Fletcher et al (7) underestimates the proportion of susceptible smokers(8).  Despite 
this controversy, the evidence is clear that pulmonary response to cigarette smoke 
exposure, as indicated by either spirometry or COPD diagnosis, varies substantially 
among smokers.  Indeed, a large cross-sectional study found that only an estimated 
15% of the variation in lung function was explained by smoking parameters(9).  
1 
 The variability in risk of disease in cigarette smokers constitutes an unresolved 
and key interest in etiologic research on COPD: what distinguishes those smokers who 
develop airflow obstruction from those who do not? Understanding the answer to this 
question is an important step in understanding COPD pathogenesis and is likely to 
contribute to primary and secondary prevention efforts.  Currently, available therapies 
for COPD produce only modest benefits, and most treatments do not slow the rate of 
decline in FEV1(10, 11).  Thus, research in this area is a high priority, particularly in 
light of the contribution of COPD to mortality, morbidity, and rising health care 
costs(1-3, 12, 13) .  
The hypothesis investigated in this dissertation is that variability in antioxidant 
defenses contributes to the risk of COPD. This hypothesis was developed on the basis 
of several key observations.  First, cigarette smoke is a rich source of oxidative stress, 
providing an estimated 1014 oxidants per puff(14), an immediate challenge to the 
antioxidant defenses in the lungs.  Cigarette smokers and COPD patients have elevated 
levels of biomarkers of oxidative stress both in the lungs and systemically (15-20).  
Transient increases in oxidative stress biomarkers are also seen in COPD patients 
during an exacerbation, a period of greatly diminished lung function, often associated 
with a respiratory infection.  The increased oxidative stress observed in smokers 
provokes inflammatory responses and the inactivation of antiproteinases; both 
increased inflammation and an imbalance between proteinases and antiproteinases are 
contributors to the pathogenesis of COPD.   
Furthermore, evidence from observational studies of dietary intake of nutrients 
with antioxidant function, or serum antioxidant concentration, studied in relation to 
lung outcomes suggest that lower levels of antioxidant defense are associated with 
decreased lung function and higher COPD risk(21-33). Whether improving 
antioxidant defenses, particularly through changing nutritional status, would 
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 ameliorate lung disease risk is a fundamental question in COPD prevention, and the 
research aims addressed in this dissertation were designed to provide further evidence 
relative to this question. Specifically, a series of studies was designed to address 
whether variability in antioxidant defenses contributes to the susceptibility to COPD 
and lower lung function, especially in current or past smokers.   
The first project extended previous work on the association between dietary 
antioxidant intake and lung function outcomes by studying the question longitudinally 
in an older population comprised of both European and African Americans. Few prior 
studies provide evidence on lung function trajectory, although rate of change in lung 
function is a more informative marker of disease susceptibility than cross-sectional 
measurements.  Indeed rate of change in FEV1, a parameter of lung function, is an 
independent indicator of subsequent mortality risk at the population level. Also, prior 
studies were conducted on populations in middle age, and very few studies in elderly 
populations (and no longitudinal studies) have been conducted. This gap in the 
literature needed to be addressed; indeed, the highest risk group is the aging 
population, where both compromised antioxidant defenses and steep rates of decline in 
lung function co-exist. Finally, there has been no evaluation of this question in 
populations with a high proportion of African American seniors, although the 
distribution of lung function in this group is lower in comparison to European 
American peers.  Thus, the first project investigated the relation of dietary intake of 
nutrients with antioxidant properties in relation to rate of change in lung function, and 
carefully considered whether associations were different by cigarette smoke exposure. 
Although the evidence from this and previous work on the association between 
antioxidant nutrition and lung function is compelling, observational studies of dietary 
exposures are limited in causal inference. Thus, the second and third projects 
investigated the question with different tools by studying whether sequence variation 
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 in genes that play a role in host antioxidant defenses are associated with lung 
outcomes.  Several lines of evidence supported this approach, including findings of 
familial aggregation of COPD risk (34-37), and twin studies suggest heritability of 
lung function (38).  Heritability estimates improved when data are limited to 
participants with a smoking history, suggesting a role for a gene-environment 
interaction. 
On the basis of the fairly preliminary work in this area and to ground subsequent 
work, for the second project a systematic overview of the literature was completed, 
with a rigorous evaluation of studies on a broad range of enzymes with known 
antioxidant function.  The review summarizes the evidence base to inform the 
continued investigation of antioxidant enzymes as contributors to COPD disease risk, 
and highlights promising results and apparent gaps to direct future work.  The review 
considers evidence on sequence variation in genes and on differential expression of 
genes, as both can inform our understanding of the relation between antioxidant 
enzymes and disease risk. 
The third project was guided by the results of the systematic review, and this 
project investigated sequence variation in genes encoding antioxidant enzymes in 
relation to lung function phenotypes in an elderly cohort.  In completing the 
systematic review, we identified the need for a network-driven approach that carefully 
considers effect modification by cigarette smoking and more fully characterizes the 
variation in a broad range of antioxidant-related candidate genes.  Thus, this project 
investigates the association between sequence variants across the genes and regulatory 
regions of an entire network of antioxidant enzymes that are expressed in the lungs in 
relation to lung function phenotypes of central importance in COPD risk.  This 
association is considered in a cohort of the elderly, the Health, Aging, and Body 
Composition Study.  
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 5 
Overall, the three projects comprising the dissertation research will contribute to 
the understanding of the role of variability in antioxidant defenses in determining lung 
function outcomes (and, subsequently, COPD disease risk) upon cigarette smoke 
exposure.  With limited treatment and prevention options (beyond smoking cessation) 
and the current inability to identify the smokers who belong to the “susceptible 
minority” with enhanced disease risk, establishing an association between antioxidant 
defenses and risk is an important contribution to current disease strategies and further 
etiological investigations.  Given the anticipated increases in public health burden 
associated with this disease, such a contribution would be of considerable importance.  
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 Abstract  
 
Increased antioxidant defenses are hypothesized to decrease age- and smoking-related 
decline in lung function. The relation of dietary antioxidants, smoking, and forced 
expiratory volume in the 1st second of effort (FEV1) was investigated in community-
dwelling adults (aged 70-79 yrs at baseline) in the Health, Aging, and Body 
Composition Study, (Memphis, TN and Pittsburgh, PA; 1997-2007). 2,065 
participants completed a food frequency questionnaire, self-reported smoking history, 
and had at least 2 measurements of FEV1.  In continuing smokers (reported smoking at 
baseline and follow-up), high vitamin C and high intake of fruits and vegetables were 
associated with an 18 and 29 ml/year slower rate of FEV1 decline compared to low 
intake (P=0.0004 and 0.003, respectively). In quitters (reported smoking at baseline, 
but quit during follow-up), high intake was associated with a slower rate of decline for 
each nutrient studied (p<0.01, all models): the rate of FEV1 decline was attenuated by 
56, 83, 73, and 33 ml/year in high versus low consumers of vitamins C, E, beta-
carotene and fruits/vegetables, respectively.  Antioxidant intake was not associated 
with FEV1 decline in non-smoking participants.  Increasing the intake of nutrients with 
antioxidant properties may attenuate lung function decline in older adults who smoke 
or have smoked.   
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 Introduction 
 
The process of aging has been described as the accumulation of oxidative 
damage that is incompletely repaired by the body’s antioxidant defenses (1).  The 
cause of this damage is assault by free radicals produced in the body via normal 
metabolic processes and inflammation, and by free radicals from the environment, 
including sources such as smoking and noxious gases.  In the lungs, aging is 
associated with declining lung function, with rate of decline increasing with advancing 
age (2).  In older adults, steeper rates of decline are associated with both an increased 
risk of chronic obstructive pulmonary disease (COPD) and an increased risk of all-
cause mortality (2, 3).  Exposure to cigarette smoke contributes to oxidative stress and 
accelerates the “aging” of the lung, resulting in the greater reductions in lung function 
observed among persons with a history of cigarette smoking (3-5).       
The large surface area of the lungs is in constant contact with oxidants from 
the environment, but antioxidant defenses limit the damage associated with breathing 
oxygen. When these antioxidant defenses are overwhelmed, oxidative stress can 
provoke and enhance both the inflammation (6) and antiprotease inactivation (7) 
associated with COPD and contribute directly to tissue damage (8).  Enhancing 
antioxidant defenses is hypothesized to reduce the accumulation of oxidative damage, 
thus potentially slowing the rate of decline in lung function associated with aging and 
smoking.   
In support of this hypothesis, observational epidemiologic studies of dietary 
antioxidant intake, serum antioxidant concentration, and lung outcomes (spirometry at 
one point, rate of decline, and risk of COPD) suggest that lower levels of antioxidant 
defense are associated with worse outcomes (9-14) and higher COPD mortality risk 
(15). Although older adults are at the greatest risk of steep rates of decline in FEV1 
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and would experience the greatest increases in quality of life with prevention, there is 
little research on the association between dietary antioxidants and FEV1 in this age 
group.  In addition, most studies of antioxidants and FEV1 are cross-sectional, despite 
the expectation that rate of FEV1 decline is a more informative indicator of mortality 
and COPD risk (2).  To address the need for longitudinal evidence in older 
populations, we tested the hypothesis that dietary antioxidants modify the association 
of smoke exposure with the rate of FEV1 decline in the cohort of older adult 
participants of the Health, Aging, and Body Composition study (Health ABC).  
Because dietary antioxidants are expected to directly protect against oxidative stress 
associated with current smoking, the primary analysis focused on the decline in FEV1 
over 4 years of follow-up with concurrent measurements of both dietary intake and 
smoking status.  A secondary analysis investigated the hypothesis that a single 
measurement of antioxidant intake near study entry was associated with attenuated 
rate of decline during nine years of follow-up.  Some of these results have been 
previously reported in the form of an abstract (16, 17). 
 
Materials and Methods 
 
The Health ABC is a prospective cohort study of 3,075 community-dwelling 
older adults, aged 70-79 years at baseline.  High-functioning adults were recruited; 
specifically, participants reported themselves able to do the following without 
difficulty: walk ¼ mile, climb 10 steps, and perform activities of daily living.  Details 
of this population have been previously published (18).  The Health ABC study was 
approved by the institutional review boards of the University of Pittsburgh and the 
University of Tennessee; this study was approved by the Institutional Review Board 
for Human Participants at Cornell University. 
Exclusion criteria included: missing food frequency questionnaire (FFQ) data 
or smoking history, < 2 spirometry tests with acceptable quality control scores 
(acceptable quality = no early coughs, no early termination, limited extrapolated 
volume, and ≤ 200 ml between two best FEV1 values), or prevalent lung disease: 
spirometry-defined COPD, physician’s diagnosis of COPD only, and asthma.     
The 4-year follow-up analysis assessed the relation between dietary antioxidant 
intake data collected at the 1 year follow-up and lung function measured at study entry 
and 4 years later.  The 9-year follow-up analysis assessed the relation between dietary 
antioxidant intake data collected at the 1 year follow-up and lung function data 
collected up to four times over a 9 year time period.  This analysis included 
participants with at least 2 acceptable spirometry tests from any of the 4 examinations 
(study entry, follow-up studies at 4, 7 and 9 years).   
Study variables 
Spirometry was conducted during the clinical visit at study entry, and at the 4, 
7, and 9 year follow-up examinations and tests were done according to standard 
guidelines (18).  
Smoking exposure was assessed by interview at baseline and at each follow-up 
visit.  For the 4-year follow-up analysis, smoking status was categorized as continuing 
smoker (report of smoking at each visit), quitter (report smoking at baseline visit but 
not at follow-up), former smoker (report history of smoking prior to baseline), and 
never smoker (report never smoking prior to baseline [smoked less than 100 cigarettes 
in lifetime]).  For the 9-year-follow-up analysis, smoking status variables were defined 
as above for continuing, former, and never smokers, and a category of intermittent 
smoking was added to reflect participants whose smoking status changed over follow-
up.  Smoking parameters included pack years (average packs smoked per day 
multiplied by number of years smoking) and current smoking status at each follow-up 
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 examination.  
Dietary antioxidant intake was determined by a modified Block FFQ 
administered at the 12 month examination (details previously published (19)), which 
captures usual diet in the preceding 12 month period. The intake of nutrients with 
antioxidant properties was measured by whole food intake (fruits and vegetables, 
servings per day) and calculated micronutrients (vitamins C and E, and β-carotene).  
Due to limitations in data regarding dose and contents of supplements/multivitamins, 
analysis of antioxidant intake from these sources was not conducted. Power terms and 
categorical variables were created to determine if continuous variables had a linear 
relation with the outcome; we found no evidence of non-linearity and continuous 
coding was used for each of the nutrient intake variables.  Product terms were created 
to test interaction between measures of oxidative stress (smoking) and antioxidant 
status (dietary antioxidant intake).  
Data analysis 
Linear mixed models (Proc MIXED, SAS) were used to assess the association 
of predictors (dietary antioxidant intake and smoking parameters) with FEV1.  Age, 
gender, height, race, Health ABC study site (Memphis, Tennessee or Pittsburgh, 
Pennsylvania) were included as covariates in all models.  Rate of decline was 
calculated as the difference between FEV1 measurements at each time point divided 
by the time between the measurements, and association between predictors and rate of 
decline was determined by evaluating interaction terms between the predictor and a 
time variable.      
A variable quantifying the amount of time elapsed from study entry to each 
subsequent FEV1 measurement was included in all of the models; in the 9-year follow-
up analysis, the square and cube of the elapsed time variable were highly statistically 
significant (p<0.0001) and were also included. 
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Fruit and vegetable intake were considered as a single variable defined as the 
sum of the intake of fruits and vegetables (servings per day).  Results of each of the 
models were further evaluated by comparing predicted FEV1 values for high and low 
intake (high and low intake defined as the 90th and the 10th percentile, respectively, of 
the cohort distribution of intake for each of the dietary variables).  Predicted FEV1 
values were calculated using model parameters and estimated within the mixed 
procedure of SAS.     
All analyses were conducted using SAS v 9.1 (SAS, Cary, NC). 
 
Results 
Of the 2,216 participants with dietary and smoking data and without prevalent 
lung disease (72% of all Health ABC participants), 1,443 had valid spirometry at 
baseline and after 4 years of follow-up (65%, included in the 4-year follow-up 
analysis), and 1,720 had at least 2 valid spirometry tests over 9 years of follow-up 
(78%, included in the 9-year follow-up analysis); 774 participants had valid 
spirometry at all four time points.  The proportion of eligible (i.e., still alive) 
participants who did not have spirometry data increased over the follow-up period: 
7%, 19%, 27% and 29% were missing, respectively, at the 4 successive examinations. 
Among participants who completed spirometry, about 94% of tests met acceptability 
criteria at each examination.  
Baseline characteristics of participants included in either of the analyses or 
excluded from the study are given (Table 2.1).  Inclusion was associated with 
survivorship and, as expected, participants in the longitudinal analyses were more 
likely to be nonsmokers and, if they were smokers, to have smoked less on average 
over their lifetime.     
 
  
Table 2.1:  Baseline Characteristics of Health, Aging, and Body Composition Participants Included and Excluded from Analyses;  
Memphis, TN and Pittsburgh, PA; 1997-2007a. 
 
 4-Year Follow-Up 
(n=1443) 
9-Year Follow-Up 
Additional Participantsb 
(n=277 ) 
Excluded  
(n=1355) 
Age, years 73.5 (2.8) 73.5 (2.9)  73.8 (2.9) 
Females (%) 731 (51%) 162 (58%) 691 (51%) 
Blacks (%) 505 (35%) 105 (38%) 671 (50%) 
Memphis, TN site (%)c  652 (45%) 155 (56%) 741 (55%) 
Former Smokers (%) 640 (44%) 128 (46%) 636 (47%) 
Current Smokers (%) 97 (7%) 18 (7%) 203 (15%)  
Packyears  30.3 (27.7) 29.7 (26.9)  38.6 (31.4)  
Dietary Intake    
     Vitamin C, mg/day 146 (76) 143 (76)  146 (81)  
     Vitamin E, α-TE/day 11.1 (6.9) 10.9 (6.1) 11.0 (6.9) 
     β-carotene, μg/day 3392 (2532) 3534 (3036) 3631 (3199)  
     Fruits, servings/day 2.0 (1.2) 2.0 (1.1) 1.9 (1.2) 
     Vegetables, servings/day 3.0 (1.9) 3.0 (1.9) 2.9 (1.9) 
FEV1 at baseline, mld  2326 (601) 2209 (600) 1945 (632)  
17
Abbreviations: α-Tocopherol Equivalents (α-TE); Forced Expiratory Volume in the 1st second of effort (FEV1); Chronic Obstructive 
Pulmonary Disease (COPD). 
a Unless otherwise indicated, mean (SD) is reported. 
b Characteristics of participants who were not included in the 4-year analysis, but who met inclusion criteria for the 9-year analysis 
(all participants in the 4-year follow-up column were included in the 9-year analysis, n=1720 total).  
cvs. Pittsburgh, PA site 
dCalculated on those with an acceptable baseline FEV1 (4-year follow-up: n=1443; 9-year follow-up additional participants: n=162; 
Excluded: n=1098)
 
 
 Rate of decline by smoking status 
Mean baseline FEV1 (adjusted for age, race, gender, height, Health ABC site, 
pulmonary drug use, pack years) in never smokers [2.32 L (95% confidence interval 
(CI) 2.29, 2.35)] and former smokers [2.33L (95% CI 2.30, 2.36)] was about 150 ml 
higher than mean baseline FEV1 in continuing smokers [2.19 L (95% CI 2.07, 2.30)] 
and intermittent smokers [2.15 ml (95% CI 2.05, 2.25)].  Cigarette smoking was 
associated with a higher rate of decline in FEV1 (P=0.05; Figure 2.1); the annual rate 
of decline in FEV1 was 50 ml/yr, 52 ml/yr, 60 ml/yr and 43 ml/yr in never, former, 
continuing, and intermittent smokers, respectively.    
 
Antioxidant intake 
The association between antioxidant intake and lung function was evaluated 
using both calculated micronutrient variables (dietary vitamin C, vitamin E, and β-
carotene) and intake of whole foods with antioxidant properties (fruits and 
vegetables).  Although dietary intake was represented with continuous variables, 
results are presented as high (90th percentile) and low (10th percentile) levels for 
convenience.  Participants with the highest burden of environmental oxidative stress 
were assumed to be continuing smokers and quitters. In these groups, high antioxidant 
intake was consistently associated with a slower rate of decline (Table 2.2), but there 
was little or no association of dietary variables to lung function decline in never and 
former smokers.   
Continuing smokers who consumed diets high in either vitamin C or vitamin E 
had slower rates of decline in FEV1 (-30 and -32 ml/year) compared to continuing 
smokers who consumed diets low in these nutrients (-48 and -47 ml/yr; P interaction = 
0.0004).  A more dramatic difference was observed between continuing smokers with 
high vs. low fruit and vegetable intake, with a 29 ml/year attenuation in rate of decline 
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Table 2.2 Difference in Rate of Decline in FEV1 for High (90th %) vs. Low (10th %) Dietary Antioxidant Intakea 
  High Intake (90th percentile) Low Intake (10th percentile) High vs. Low 
Nutrient Smoking Status Baseline 
FEV1 
4th year 
FEV1  
FEV1 
Decline 
Baseline 
FEV1 
4th year 
FEV1  
FEV1 
Decline 
Rate of 
Declineb,c,d 
Vitamin C Continuing Smoker 2129 ml 2009 ml -30 ml/year 2117 ml 1923 ml -48 ml/year +18 ml/year 
236.5 vs 65.2 mg/day Quittere 2174 ml 2181 ml +2 ml/year 2140 ml 1922 ml -54 ml/year +56 ml/year 
 Former Smoker 2334 ml 2097 ml -59 ml/year 2310 ml 2123 ml -47 ml/year -12 ml/year 
 Never Smoker 2380 ml 2174 ml -51 ml/year 2339 ml 2156 ml -46 ml/year No difference 
        (P = 0.0004) 
Vitamin E Continuing Smoker 2070 ml 1943 ml -32 ml/year 2172 ml 1982 ml -47 ml/year +16 ml/year 
19.5 vs 5.1 α-TE/day Quittere 2124 ml 2200 ml +19 ml/year 2202 ml 1947 ml -64 ml/year +83 ml/year 
 Former Smoker 2295 ml 2077 ml -54 ml/year 2339 ml 2135 ml -51 ml/year No difference 
 Never Smoker 2386 ml 2191 ml -49 ml/year 2343 ml 2148 ml -49 ml/year No difference 
        (P = 0.002) 
β-carotene Continuing Smoker 2092 ml 1926 ml -42 ml/year 2167 ml 2003 ml -41 ml/year No difference 
6592 vs 1186 µg/day Quittere 2130 ml 2211 ml +20 ml/year 2188 ml 1977 ml -53 ml/year +73  ml/year 
 Former Smoker 2301 ml 2089 ml -53 ml/year 2331 ml 2122 ml -52 ml/year No difference 
 Never Smoker 2362 ml 2159 ml -51 ml/year 2354 ml 2169 ml -46 ml/year No difference 
        (P = 0.01) 
Fruits and  Continuing Smoker 2092 ml 1994 ml -24 ml/year 2184 ml 1972 ml -53 ml/year +29 ml/year 
Vegetables Quittere 2104 ml 2038 ml -17 ml/year 2251 ml 2053 ml -50 ml/year +33 ml/year 
8 vs 2 servings/day Former Smoker 2341 ml 2105 ml -59 ml/year 2300 ml 2113 ml -47 ml/year -12 ml/year 
 Never Smoker 2375 ml 2178 ml -49 ml/year 2337 ml 2147 ml -48 ml/year No difference 
        (P = 0.003) 
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Abbreviations: α-TE, α-Tocopherol Equivalents; Forced Expiratory Volume in the 1st second of effort (FEV1);  
a Rate of decline estimated from hierarchical mixed models adjusted for age, height, race, gender, pulmonary drug use, study site, current cigarettes/day, and calorie intake 
(separate models for each listed antioxidant).  
b Positive (+) differences indicate an attenuated rate of decline in participants with higher dietary intake of nutrient considered.  
c  “No Difference” indicates difference between groups less than 10 ml/year. 
d P value given is for the interaction term for smoking status, dietary antioxidant intake, and time.  
e Estimates in this category correspond to those who quit smoking during the study follow-up. 
 
 
 (P interaction = 0.003).  No difference was observed among continuing smokers by 
intake of β-carotene.  
In the group of smokers who quit, high antioxidant intake (vs. low) was 
associated with greater attenuations in rate of decline, and the effects were greater than 
those observed in continuing smokers.  High vs. low intake was associated with a 56, 
83, and 73 ml/year slower decline for vitamins C, E, and β-carotene, respectively (Ps 
for interaction 0.0004, 0.002, and 0.01).  These differences reflect increases in 
pulmonary function over the 4 years of follow-up among quitters with higher 
antioxidant intake of these nutrients compared with the declines observed among 
quitters with low antioxidant intake.  Among smokers who quit, a high intake of fruits 
and vegetables (vs. low) was also associated with an attenuated rate of decline (33 
ml/year), and the magnitude of this attenuation was similar to that observed in 
continuing smokers (29 ml/year attenuation in rate of decline).   
 When dietary vitamin C, vitamin E, and β-carotene were included in the same 
model to account for multicollinearity, a high intake of all three antioxidants 
(compared to low intake of all) was associated with a 20 ml/year slower decline 
among continuing smokers and a 94 ml/year slower decline among quitters.  The 
statistical significance of all terms was reduced, and the interaction between vitamin 
C, smoking status, and time had the lowest p-value (P=0.08). 
When the analysis was extended to include the follow-up data on FEV1 over 
the nine year time period, all associations were attenuated. In continuing smokers 
consuming a diet high in antioxidants, models incorporating all available lung function 
data yielded effects of similar magnitude:  in continuing smokers high vitamin C was 
associated with an 18 ml/year slower decline; high vitamin E was associated with an 
18 ml/year slower decline; and high fruit and vegetable intake was associated with a 
14 ml/year slower decline.  No associations were observed among intermittent, 
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 former, or never smokers in the 9-year follow-up analysis.  No associations were 
observed with dietary intake of β-carotene in the 9-year follow-up analysis.   
The 9-year analysis was limited to the 1,443 participants included in the 4-year 
analysis to determine if the difference in results was due to selection bias instead of 
the increased time of follow-up.  This analysis yielded larger associations with 
increased statistical significance (though still not the same level of statistical 
significance as in the 4-year analysis):  in continuing smokers, high vitamin C was 
associated with an 23 ml/year slower decline (P=0.06); high vitamin E was associated 
with a 27 ml/year slower decline (P=0.20); and high fruit and vegetable intake was 
associated with 21 ml/year slower decline (P=0.32).  No associations were observed 
among intermittent, former, or never smokers, and no associations were observed with 
dietary intake of β-carotene.   
 
Discussion 
 
Dietary antioxidant intake is a potentially modifiable predictor of the decline in 
FEV1 in this longitudinal study of well-functioning older adults.  Among the Health 
ABC participants, consuming a diet high in antioxidants was associated with an 
attenuated slope of decline in lung function in current smokers, the population 
subgroup at greatest risk of lung-related disability and death.  In smokers, higher 
intakes of vitamin C, vitamin E, β-carotene, and fruits and vegetables were associated 
with meaningful differences in the trajectory of change in FEV1.  In Health ABC 
cohort participants who continued to smoke over four years of follow-up, Vitamin C 
and fruit and vegetable intake had the strongest associations; smokers with high 
intakes had 18 and 28 ml/year lower rate of decline in FEV1 compared to smokers 
with low intakes. In participants who quit smoking, all dietary antioxidants had strong 
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 inverse associations with rate of decline: quitters with high intakes of vitamin E, β-
carotene, vitamin C and fruit and vegetables had 83, 73, 52 and 32 ml/year lower rate 
of decline in FEV1, respectively, compared to quitters with low intake.  Although the 
association of fruits and vegetables was similar in continuing smokers and quitters, 
suggesting a broad role for these foods in persons who are smoke-exposed, the 
stronger findings for vitamins C, E, and β-carotene in quitters may signify the 
importance of a range of antioxidants to optimally support the transition from current 
to former smoker.  
Prior studies of younger adult populations reported associations between 
dietary antioxidant intake and rate of decline in FEV1 similar in magnitude to the 
Health ABC findings. Changes over time in the consumption of fresh fruit were 
associated with rate of decline in FEV1 in healthy British adults (age 18-73): 
participants with the largest decrease in fruit intake had a steeper rate of decline in 
FEV1 (89 ml/year and 133 ml/year steeper for men and women) compared to 
participants with no change in fruit intake (20), and effects were strongest among 
cigarette smokers.  This study also reported that average fruit intake had little or no 
association with rate of decline, underscoring the importance of appropriately timed 
measurements of dietary intake.  In middle-aged Welshmen (age 45-59) followed for 5 
years, the rate of FEV1 decline was 10 – 15 ml/year slower in men with high apple 
intake compared to men with low intake; however, no associations were found for 
vitamins C, E, and β-carotene (9).  Nottingham adults (age 18-70) consuming diets 
high in vitamin C (100 mg higher than low vitamin C diets) had an attenuation in the 
rate of decline in FEV1 (by about 6 ml/yr), but no associations were found for vitamins 
A and E (14).    In a cohort of heavy smoking French adults (age 20-44), higher levels 
of serum β-carotene and serum vitamin E were associated with slower rates of decline 
in FEV1 (21).   
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 Despite the relatively few longitudinal studies of dietary antioxidants and lung 
function, most of the cross-sectional studies that have investigated this hypothesis 
reported positive associations between vitamins C and E, β-carotene, fruits and 
vegetables and lung outcomes (9-15, 20-26). On closer examination, the strongest 
effect sizes were often identified in cigarette smokers.   
Among the Health ABC participants classified as never and former smokers, 
the intake of nutrients and foods with antioxidant properties had little or no association 
with the rate of decline in FEV1. These findings are consistent with the hypothesis that 
a protective effect of nutrients with antioxidant properties is expected primarily in 
persons with a high burden of oxidative stress. Thus, the role of dietary antioxidants 
may be to provide additional functional capacity to reduce damage from exposure to 
exogenous oxidants.  The findings suggest a testable hypothesis, which could be 
pursued in other studies: non-smokers may not benefit from increasing the intake of 
nutrients with antioxidant properties either because their overall level of oxidant 
burden is low enough to be well-managed by endogenous capacity, or because the 
dietary antioxidants considered in Health ABC are not efficacious at bolstering 
endogenous antioxidant capacity.  
The Health ABC study allows a closer look at the rate of decline in lung 
function associated with smoking status in a cohort of older adults.  Of particular 
interest is the difference in rate of decline in FEV1 between continuing smokers (60 
ml/year) and intermittent smokers (43 ml/year).  These data suggest that at advanced 
ages significant functional improvements may be attained with smoking cessation 
(even with relapses).  Attenuating the rate of decline is especially important in the 
subgroup of smokers, because, on average, smokers have lower starting FEV1 values 
(150 ml lower), and are therefore at greater risk of disability and death.   
The findings in Health ABC underscore the importance of timing of exposure 
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 measurements relative to outcome.  If the balance between antioxidants and oxidants 
in the lung compartment is expected to affect the rate of decline in lung function, then 
concurrent measurements of diet, smoking parameters, and lung function are likely to 
be most informative.  In the Health ABC study, the association between antioxidant 
intake and rate of decline in smokers is strongest (effect size and statistical 
significance) when the analysis is limited to the time period with concurrent 
measurements. When the analysis is extended to investigate the relation of baseline 
diet to longer-term effects on rate of decline in FEV1, the magnitude of the 
associations were similar, but less statistically significant.  Including endpoint 
measurements separated in time from exposure measurements may introduce “noise” 
in the analysis.  In the Health ABC study, the dietary intake of antioxidants was 
estimated from a single food frequency questionnaire administered in the first 12 
months of the study.  In this vulnerable age group, many factors are associated with 
changes in dietary quality including new disease diagnoses, the onset of functional 
impairment, changes in living situation, loss of a spouse, etc.(27-29).  Thus, the 
strongest analytic approach is arguably one that limits consideration of pulmonary 
function changes to the same time period in which diet was measured. 
Our study has several strengths.  The study used data from a large, prospective 
cohort study of elderly people; a population which stands to benefit from research 
aimed at understanding how to prevent loss of lung function. The quality control 
standards for spirometry in Health ABC followed best practice, as evidenced by the 
excellent overall quality of the pulmonary function data.  The use of two separate 
methods to estimate dietary intake of nutrients with antioxidant properties, 
micronutrients and whole foods, yielded similar results confirming our assumption 
that the findings represent true associations of diet on lung function. The consideration 
of simultaneous models including all nutrients diminishes the possibility that the 
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 observed associations were primarily driven by a single dietary constituent.   
There are also several limitations of the study. While the use of antioxidant 
supplements is expected to contribute to overall antioxidant status, limitations in the 
Health ABC data collection methods for supplements precluded their further 
consideration.  A study conducted in an elderly cohort raises a concern about survivor 
bias: non-random loss-to-follow-up results in healthier participants at later stages of 
the study.  Survivor bias is evident when participants contributing data at each 
successive measurement are compared: participants who were followed for longer 
were younger, more often female, and smoked less at baseline.  If participants who did 
not remain in the study had a greater burden of oxidative stress (given their smoking 
history and age, this may be a reasonable hypothesis) then, in light of the findings in 
participants with the highest burden of oxidative stress, even stronger associations 
than those observed might be expected.  
In summary, this study of older adults (70-79 years at baseline) supports the 
hypothesis that nutrients with antioxidant properties are associated with a slower rate 
of FEV1 decline in current and quitting smokers.  Whether changing the intake of 
foods rich in nutrients with antioxidant properties will lead to a slower rate of decline 
in a FEV1 remains to be demonstrated, but the results from the Health ABC cohort 
support this inference.  
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 CHAPTER 3 
GENETIC VARIATION AND GENE EXPRESSION IN ANTIOXIDANT-
RELATED ENZYMES AND RISK OF CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE: A SYSTEMATIC REVIEW 
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Abstract 
Observational epidemiologic studies of dietary antioxidant intake, serum 
antioxidant concentration, and lung outcomes suggest that lower levels of antioxidant 
defenses are associated with decreased lung function.  Another approach to 
understanding the role of oxidant/antioxidant imbalance in risk of Chronic Obstructive 
Pulmonary Disease (COPD) is to investigate the role of genetic variation in 
antioxidant enzymes, and indeed family-based studies suggest a heritable component 
to lung disease.  Many studies of the genes encoding antioxidant enzymes have 
considered COPD or COPD-related outcomes, and a systematic review is needed to 
summarise the evidence to date, and to provide insights for further research. 
Genetic association studies of antioxidant enzymes and COPD/COPD-related 
traits, and comparative gene expression studies with disease or smoking as the 
exposure were systematically identified and reviewed.  Antioxidant enzymes 
considered included enzymes involved in glutathione (GSH) metabolism, in the 
thioredoxin (TXN) system, superoxide dismutases (SOD), and catalase (CAT).   
A total of 29 genetic association and 14 comparative gene expression studies 
met the inclusion criteria. The strongest and most consistent effects were in the genes 
GCL, GSTM1, GSTP1, and SOD3.  This review also highlights the lack of studies for 
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 genes of interest, particularly GSR, GGT, and those related to TXN. There were limited 
opportunities to evaluate a gene’s contribution to disease risk through a synthesis of 
results from different study designs, as the majority of studies considered either 
association of sequence variants with disease or effect of disease on gene expression.  
Network-driven approaches that consider potential interaction between genes and 
among genes, smoke exposure, and antioxidant intake are needed to fully characterise 
the role of oxidant/antioxidant balance in pathogenesis. 
 
Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is characterised by the 
development of airflow limitation that is not fully reversible. COPD is a major, and 
growing, public health burden (1). 
Smoking is the most important risk factor for COPD; however, there is 
considerable variation in the response to smoke exposure (2), and it has been 
estimated that only 15% of the variation in lung function is explained by smoking 
parameters (3). While not discounting the paramount importance of smoke exposure in 
the development of COPD, clearly other factors are significant. Genetic variation is a 
prime candidate, and many recent studies explore the contribution of genetic variation 
to inter-individual differences in the response to cigarette smoke. 
This review focuses on genes related to antioxidant activity, as oxidant-rich 
cigarette smoke strains the antioxidant defenses of the lungs, leading to direct tissue 
damage and contributing to the inflammation and antiprotease inactivation seen in 
COPD. This hypothesis is supported by epidemiologic studies associating low dietary 
antioxidant intake and serum antioxidant concentration with decreased lung function 
(4-9) and increased COPD mortality risk (10).   
 Many genetic association studies and comparative expression studies 
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 investigate the relation between genes coding for antioxidant enzymes and either 
COPD or associated traits.  An overview of the evidence is warranted to ascertain 
whether the pattern of published results suggests directions for future research, or 
whether there are apparent gaps that need to be addressed. Both genetic association 
studies and gene expression studies were included: polymorphisms can affect disease 
risk in ways that may or may not be mediated by changes in expression, and 
expression studies can provide a snapshot of the adaptive response to an exposure. 
Thus, we conducted a systematic review of the literature to characterise the evidence 
that genes coding for antioxidant enzymes contribute to the aetiology of COPD and 
related traits.   
 
Methods  
The selection of genes was based mainly on delineating important proteins and 
the networks of genes that may influence the amount or function of those proteins 
(Figure 3.1).  As glutathione (GSH) is an antioxidant that plays a significant role in the 
lung, genes encoding GSH-associated enzymes were selected.  Thioredoxin, which 
reduces oxidized glutathione and has an antioxidant function that overlaps GSH 
function, was included with genes encoding associated enzymes.  Catalase and 
superoxide dismutase, two classical antioxidant enzymes of the lung, were also 
selected.  Searches of PubMed were performed up to August 2007 (further details in 
Supplement A.1).  Published papers considering gene-disease association or 
differential gene expression in adult humans were selected.  Association studies were 
included if the outcome was disease or lung function.  Expression studies were 
included if the experimental exposure was disease status or smoking and if expression 
was measured in pulmonary tissues or cells.   
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Results 
 A total of 29 genetic association studies and 14 expression studies were 
identified (Table A.2).  The results of these studies are presented in supplemental 
tables (Association Studies, Table A.3; Expression Studies, Table A.4) and 
summarized below. 
Glutathione Synthesis 
Three enzymes that relate to glutathione synthesis were considered: gamma-
glutamyl transpeptidase (GGT, no studies found), glutamate-cysteine ligase (GCL), 
and glutathione synthetase (GSS). A substitution in the promoter region of GCLM 
(GCL’s  
modulatory subunit), leading to decreased glutathione levels (11), was associated with 
a 3-fold increased risk of COPD in Chinese smokers (12).  In the single study of a 
substitution in GCL’s catalytic subunit (GCLC) that results in decreased expression 
(13), an increased prevalence was observed in patients vs. healthy controls (OR 1.83, 
95% CI[1.00, 3.36]) (14). 
Expression studies of glutathione synthesis compared expression in COPD 
patients with asymptomatic smokers and/or nonsmokers. Eight of the 9 comparisons 
of GCLC expression in lung epithelium found upregulation with disease (15-18).  Two 
comparisons of GCLM expression in lung epithelium of lung tumor patients with and 
without COPD showed decreased GCLM expression with disease (17), while the 
single study of COPD patients without lung tumor found upregulation (18).  
There were 4 comparisons of GCL expression in lung epithelium of 
asymptomatic smokers and nonsmokers: expression of both subunits was increased in 
smokers who were healthy volunteers (18, 19) and unchanged or decreased in smokers 
with lung tumor (17).  
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 Expression of the GCL subunits in alveolar macrophages/inflammatory cells 
showed a more consistent pattern.  Both GCLC (16, 17, 20) and GCLM (20) were 
increased in COPD patients vs. smokers, and smokers had lower expression of both 
subunits compared to nonsmokers (17, 20). A 27% upregulation of the mRNA of GSS, 
the final step of GSH synthesis, was reported in smokers vs. nonsmokers (p=0.08) 
(19), but was not replicated in comparisons of nonsmokers with either asymptomatic 
smokers or COPD patients (18, 19).  
Antioxidant Activity of GSH and Recycling 
Glutathione peroxidase (GPX), glutaredoxin (GLRX), glutathione reductase 
(GSR), and glucose-6-phosphate dehydrogenase (G6PD) were considered for their 
role in the antioxidant activity of GSH and in GSH recycling. There were no 
association studies of variants in these genes.   
Two studies evaluated expression in COPD patients versus healthy controls.  
In the single study of GPX2, it was strongly upregulated in COPD patients at all stages 
compared to nonsmokers (and modestly upregulated compared to smokers) (18).  
GPX3 was upregulated in COPD patients compared to nonsmokers, though this 
difference was not seen in comparison with asymptomatic smokers (18, 21).   There 
was little evidence of differential regulation of GPX4, GPX5, or GPX7 by disease 
status (18).   
GPX2 showed a 3 to 5-fold upregulation in epithelial cells of smokers 
compared to nonsmokers.(18, 19)  Each of the 4 studies of GPX3 expression in 
epithelial cells reported upregulation in smokers: two studies found a 2-fold difference 
(19, 22), and a study of alveolar macrophages reported similar differences (22).   
Two expression studies evaluated regulation of GLRX.  A statistically 
significant downregulation was observed in the tissue homogenate of COPD patients 
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 compared to smokers (patients had either resection for lung tumor or lung 
transplantation for severe COPD) (23), but similar results were not observed in an 
analysis of bronchial epithelial cells (18).  A statistically significant upregulation of 
GLRX in the sputum of COPD patients in exacerbation was reported vs. nonsmokers 
(23).  
The sole comparison of GSR expression in epithelial cells by disease groups 
showed upregulation in COPD patients (18).  In the 2 comparisons by smoking status, 
upregulation was observed among smokers (18, 19). Very similar results were found 
in the 3 studies of G6PD expression: 2-fold upregulation in epithelial cells (18, 19) 
and in alveolar macrophages (24).     
In agreement with biological networks, the 4 expression studies that considered 
GPX (GPX1, GPX2, and GPX3), GSR, and G6PD all showed upregulation of each of 
these genes with smoking. 
GSH Conjugation and Export 
 There were 24 association and 4 expression studies of Glutathione S-
Transferases (GSTs), which play a role in GSH conjugation and export. 
A homozygous deletion of GSTM1, resulting in a complete lack of activity 
(25), was associated with increased COPD risk in 3 of 7 association studies (range in 
OR: 2.2 to 8.0) (26-28).  The prevalence of the deletion was increased in emphysema 
patients compared to non-diseased participants (29, 30), though no association was 
observed with emphysematous changes in heavy smokers (31).  Both studies of 
chronic bronchitis reported a 3-fold increased risk associated with the null genotype 
(32, 33).    
Five studies investigated the association of the GSTM1 deletion with COPD-
related quantitative traits.  Conflicting evidence was reported: 1 of 2 studies of rate of 
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 FEV1 decline reported an association in men only (34) and 1 of 3 studies of FEV1% 
predicted reported lower lung function with the null genotype (35).  In a single study 
of FVC % predicted, the null genotype was significantly associated with decreased 
lung function (35). However, it was not associated with increased rate of FVC decline 
(34).  Null genotype was associated with a steeper rate of FEF25-75 decline (among 
men) in one study (34).  
In GSTP1, the Ile105Val substitution, which causes altered affinity for specific 
substrates (36), was associated with COPD-related outcomes.  A protective effect of 
the heterozygous genotype was reported in 7 of 11 studies of COPD patients vs. 
asymptomatic participants; the magnitude of the effect varied and was statistically 
significant in 2 studies (37, 38).  A study of smokers with emphysematous changes 
(vs. normal smokers) reported a protective effect of heterozygosity (31).  However, 7 
of 10 studies of the homozygous variant genotype in relation to COPD risk reported an 
increased risk: the difference was statistically significant in one study (39) and 4 
estimates were based on small numbers.   
The Ile105Val genotype had little or no relation to the rate of decline in FEV1, 
although the direction of effect was consistent with the hypothesis: risk was increased 
in those homozygous for the variant allele (34).  Greater effect sizes were found for 
risk of being in the tails of the FEV1% predicted distribution (40), but there was little 
or no continuous relation with FEV1% predicted (41).  
A GSTP1 polymorphism with unknown biological effect (Ala114Val) was 
investigated in 3 studies.  One study of Indian smokers observed a statistically 
significant graded increase in prevalence of COPD with the variant allele (39), but a 
similar association with emphysema risk was not observed in an American population 
(30).  In 3 comparisons of lung function within disease groups, statistically 
significantly lower lung function was observed with the variant allele in COPD 
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 patients (39), but not in emphysema patients (41) or asymptomatic smokers (39). 
There was little or no association of a homozygous deletion of GSTT1 with 
COPD risk; 3 of 4 studies reported a slightly decreased risk of disease with the null 
genotype, but the interval estimates of the effect were wide.  There was no association 
of GSTT1 null and risk of emphysematous changes in smokers (31). Three of 4 studies 
of lung function reported an association: null genotype was associated with a steeper 
decline in FEV1 in a general population (42), with steeper decline in FEV1, FVC, and 
FEF25-75 among men (34), and with an increased risk of being in the lowest compared 
to the highest group of % predicted FEV1 (40).  The only study of mGST1 found no 
association between 4 markers and FEV1 % predicted (41). 
There were 3 studies of gene expression differences by disease group.  
Upregulation of GSTM3 and mGST1 expression was observed in COPD patients (18).  
GSTO1 was significantly downregulated in the single study of lung tissue and sputum 
from COPD patients with lung tumor (43), but was upregulated in the epithelial cells 
of patients with COPD only (less severe stages) (18).   Four studies investigated the 
expression of GSTs by smoking status.  Both studies of GSTA1 expression showed 
upregulation among smokers in lung tissue (18, 21). Statistically significant 
upregulation was associated with smoking in a single study of GSTA2 (19).   GSTM3 
expression was increased among smokers to the same extent (approximately 50%) in 
both studies of epithelial cells (18, 19).  There was some evidence of upregulation of 
mGST1 among smokers in 2 studies (18, 19).  In 6 of 7 comparisons of GSTO1 
expression in various lung tissues, expression was unrelated to smoking.   
Thioredoxin Metabolism 
Thioredoxin metabolism was evaluated by considering the enzymes 
thioredoxin (TXN), thioredoxin reductase (TXNRD), and peroxiredoxin (PRDX).  No 
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 association studies and 2 expression studies were found. A single study considering 
epithelial cell expression in COPD vs. non-diseased reported upregulation of TXN, 
TXNRD1, and PRDX1 with disease, and downregulation of PRDX5 with disease (18). 
Both studies of expression by smoking status reported increased expression of TXN 
and TXNRD1 with smoking (18, 19).  In the study that also evaluated peroxiredoxins, 
PRDX1 was upregulated and PRDX3 and PRDX5 were both downregulated in 
smokers (18).          
Other Enzymes 
 Two classic antioxidants, superoxide dismutase (SOD) and catalase (CAT) 
were considered.  Three association studies (evaluating 5 variants) and 6 expression 
studies were identified.   
There was no association between an intronic SNP in SOD1 and COPD.  
SOD2 Val16Ala was associated with disease in a Chinese population (44), but not in 
persons of European descent (41).  The association between SOD3 Arg213Gly and 
COPD was studied in 2 large populations (45, 46).  Heterozygosity was associated 
with a strong, statistically significant decreased risk of disease (~40-75% reduction)( 
45, 46) and a 70% reduction in risk of COPD hospitalization or death during follow-up 
(46).  Genotype was not associated with lung function in a general population, but 
FEV1/FVC ratio was higher among smokers with the heterozygous genotype (p=0.04) 
(46). There were no homozygous variants among diseased individuals in either study, 
precluding odds ratio calculation. 
 Three studies of SOD expression compared COPD patients to healthy controls.  
SOD activity was increased in the bronchial lavage fluid of nonsmokers with COPD 
compared to smokers with COPD and healthy controls (47).  No evidence for 
differential expression by disease status was seen in 3 studies of SOD1 (18, 21, 48).  
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 In the 6 comparisons of SOD2 in lung tumor patients with COPD versus controls, 
COPD was associated with increased SOD2 concentration (21, 48).  An increase in 
expression was not observed in the single study of COPD patients without lung tumor 
(18).  Neither of the studies of SOD3 expression in disease groups provided strong 
evidence for differential regulation by disease (18, 21).  
 Little or no evidence of differential expression of SOD1 and SOD3 by smoking 
status was observed. SOD2 was upregulated in smokers vs. nonsmokers in 3 
comparisons of epithelial cells (with one showing strong, significant upregulation) and 
downregulated in 3 other comparisons.  SOD2 was also upregulated in lung tissue 
homogenate and alveolar macrophages, but downregulated in the pulmonary blood 
vessels of smokers vs. nonsmokers. 
Two studies evaluated polymorphisms in CAT, but provided no strong 
evidence for an association of two promoter region SNPs with disease risk (44, 45).  
Two studies compared CAT expression in disease groups, with little evidence for 
differential regulation by COPD status, though statistically significant downregulation 
was observed in lung tumor patients with COPD in 1 study (21).  Three studies 
compared CAT expression by smoking status, with inconsistent results.     
Gene-Gene Interaction  
Increased risk of COPD, and decreased FEV1 % predicted among COPD 
patients, was reported for various genotype combinations that included either GSTP1 
105Val or 114Val vs. wildtype for both polymorphisms (OR 1.99 for COPD risk; 95% 
CI 1.28, 3.09) (39).  In an analysis of GSTM1 null, GSTT1 null, and GSTP1 Ile105Val, 
most combinations of the “higher risk” genotypes were associated with an increased 
risk of disease, with the strongest associations observed with the GSTP1 105Ile allele 
and the null genotype for either GSTM1 (OR 11.3; 95% CI 1.3, 98.6) or GSTT1 (OR 
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 12.1; 95% CI 1.3, 116.96) (37).  Although the combination of GSTM1 null, GSTT1 
null, and GSTP1 105Ile was not associated with COPD risk in another study (49), it 
was associated with steeper lung function decline (p=0.026)(40) and risk of rapid 
decline in lung function (OR 2.83; 95% CI 1.1, 7.2) (42).  Men with the null genotype 
for both GSTM1 and GSTT1 had 8.3 ml/year greater decline in FEV1 vs. those with at 
least one copy of both (p<0.001), with similar results reported for both FVC and 
FEF25-75 (34). The National Emphysema Treatment Trial reported little or no 
association between combinations of GSTM1 null and GSTP1 105Ile and disease (30).  
There was little or no association of GSTM1 and GSTT1 null genotypes and 
emphysematous changes in Japanese heavy smokers (31).  The combination of 
GSTM1 null, GSTP1 105 Ile/Ile, and at least one slow allele for microsomal epoxide 
hydrolase increased risk of COPD (OR 6.8; 95% CI 1.6, 17.2) (26).  The combination 
of GSTM1 null and a matrix metalloproteinase 9 polymorphism increased COPD risk 
by about 8-fold (OR 7.7; 95% CI 1.1, 53.3) (27).  
 
Discussion 
Observational epidemiologic evidence suggests a role for nutrients 
contributing to antioxidant function in the prevention of lung disease (4-9). Whether 
these findings reflect underlying biological mechanisms or methodologic bias (e.g., 
confounding) is unclear. The consideration of genetic variants that affect 
antioxidant/oxidant balance and that may be sensitive to dietary intake of antioxidants 
can help address this question. The study of genetic variants affecting antioxidant 
capacity allows an unbiased approach, in comparison to observational studies of diet, 
based in part on the principles of Mendelian randomization (50).  Thus, this review 
was designed to evaluate the evidence that antioxidant enzyme function and/or 
regulation is related to COPD risk.  
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  This systematic review included studies that addressed gene-disease 
associations as well as those that evaluated differences in gene expression.  There 
were limited opportunities to synthesise results from both approaches as genes were 
often considered either in association studies or in expression studies, yet such 
synthesis may reveal complementary data (51).  For example, a variant allele that 
leads to decreased glutathione was associated with an increased risk of COPD among 
smokers (12), and an expression study of GCLM reported upregulation in smokers 
(19).  The combined results support the hypothesis that increasing available 
glutathione in persons with a high oxidant load may protect against lung damage.  A 
lack of agreement between association and gene expression studies may also be 
informative.  While association studies suggest a protective effect of heterozygosity 
for the GSTP1 Ile105Val polymorphism in COPD, no differences in expression of 
GSTP1 were reported in smokers compared to nonsmokers, suggesting that the effect 
of the genotype is not mediated through mRNA quantity.   
Comparisons with animal studies provide an additional context in which to 
interpret the findings from human studies, but caution is warranted.  Mice and adult 
rats (in contrast to humans) synthesise ascorbate (52), which protects GSH from 
oxidation and reduces it from its disulphide form (53). The interaction between 
ascorbate and other antioxidants suggests that animal studies of genetic manipulation 
or oxidant insult may not be predictive of results in humans.  While two human studies 
of GSR expression reported significantly increased mRNA expression in the airway 
epithelial cells of asymptomatic smokers (18, 19), findings in smoke-exposed rats 
were mainly negative (54-56).  Reduction of GSSG by endogenously formed 
ascorbate may blunt the rat’s need for GSR to perform the same function. 
This review reveals very few instances where the evidence base contains 
enough information to make a strong statement of effect, but a few examples deserve 
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 mention. The GSTM1 null genotype (no enzyme activity) was consistently associated 
with increased COPD risk (26-29, 32-35, 37, 57).  A substitution in another GST, 
GSTP1 Ile105Val, which affects catalytic activity and binding affinity for particular 
substrates, was consistently inversely associated with disease (31, 34, 37, 38, 40, 58-
60). A rare substitution in SOD3, which increases plasma SOD levels, was also 
associated with a significantly decreased COPD risk (45, 46), a result supported by an 
animal study: transgenic mice overexpressing human SOD3 had attenuated lung 
damage and inflammatory response in hyperoxic conditions (61). In addition, there 
was simultaneous upregulation of GSR, GPX, and G6PD in the airway epithelial cells 
of smokers (19), highlighting the importance of a network of genes in the lung’s 
response to oxidative stress. 
Several elements of the selected interrelated pathways have received minimal 
or no attention in human studies to date.  For example, targeted disruption of the TXN 
gene produced early embryo lethality in mice (62, 63), and transgenic mice over-
expressing human TXN1 had increased survival and decreased hydroxyl radical 
production during exposure to diesel exhaust particles (64). The two studies of TXN-
related enzymes in humans reported upregulation of TXNRD1 and TXN in the airway 
epithelial cells of smokers and those with COPD (18, 19): further investigation is 
warranted. Other understudied genes of interest include GGT, PRDX6, and GLRX.  
GGT is the key enzyme in one pathway for the intracellular supply of cysteine for 
GSH synthesis: GGT-deficient mice show a reduced ability for de novo synthesis (65) 
and decreased intracellular GSH concentration (66). Furthermore, pulmonary GGT 
activity was increased during hyperoxia in rats (67), and GGT-deficient mice had 
worse survival in hyperoxic conditions (65, 66).  PRDX6 is a peroxiredoxin that uses 
GSH as a cofactor. PRDX6 null mice had more severe lung injury and significantly 
decreased survival in conditions of hyperoxia vs. wildtype (68).  Transgenic mice 
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 over-expressing PRDX6 had greater survival and attenuated lung damage in hyperoxia 
(69). Finally, GLRX comprises part of a major thiol-disulphide redox buffer in the 
cell.  The activity of this enzyme suggests a possible role in relation to the oxidation of 
GSH and the redox status of the cell, recommending it for further study.  
Several methodological considerations deserve mention. COPD aetiology is 
expected to include gene-environment interactions, given the clear role of smoking in 
this disease and the inter-individual differences in response to cigarette smoke. Thus, 
comparison groups must be carefully selected with regard to smoke exposure. In 
association studies in which the non-diseased group is comprised of non-smokers and 
the diseased group of smokers, for instance, the estimate of a true effect may be 
diluted.  Similarly, in expression studies, a comparison between individuals with 
equivalent exposures, but whose disease outcome differed may be most informative. 
Studies published in other languages were included to avoid the “Tower of Babel 
error” (70).  A comprehensive set of enzymes based on biological networks were the 
starting point for the review, however our selections may have led to inadvertent 
omission of relevant enzymes. Disturbances in a broad range of redox-related enzymes 
are likely to affect disease risk, suggesting that complex interactions cannot be 
ignored.  A broader network approach may ultimately lead to more robust 
epidemiologic findings. 
 In conclusion, the evidence summarised in this review supports the continued 
investigation of the hypothesis that variation in genes that code for enzymes that can 
alter the redox environment of the lungs may contribute to COPD risk.  Future 
directions suggested by this summary are: more network-driven approaches that 
include broader consideration of enzymes whose related, redundant and linked 
activities might alter disease risk, further integration of association and expression 
studies to determine the nature of the biological relationships that may lead to disease, 
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and careful consideration, in both study design and analysis, of environmental 
exposures (e.g., smoking and nutritional status) that are likely to modify the gene-
disease associations.  
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 Abstract  
Not all cigarette smokers develop chronic obstructive pulmonary disease (COPD), and 
discovering susceptibility factors is a high research priority. The oxidative burden of 
smoking may overwhelm antioxidant defenses if those defenses are compromised as a 
result of sequence variants in genes encoding antioxidant enzymes. This study 
explores the association between genetic variation in a broad network of antioxidant 
enzymes and lung phenotypes.  Linear models were used to evaluate associations 
among 2,387 European and African American seniors in the Health, Aging, and Body 
Composition (Health ABC) Study.  Genes encoding members of the peroxiredoxin 
and isocitrate dehydrogenase gene families were in the most statistically significant 
SNPs list and relatively common variant genotypes were associated with biologically 
meaningful differences in phenotype, suggesting these genes, especially PRDX5, 
PRDX3, IDH3A, and IDH3B, as targets of future research.  After correction for 
multiple comparisons, 4 associations remained statistically significantly associated 
with the ratio of FEV1/FVC in African Americans, as follows: interactions between a 
SNP in IDH3B with both smoking status and smoking dose (padj=0.002 and 0.01, 
respectively), and interactions between 2 SNPs in a glutaredoxin, GLRX2, with 
smoking dose (padj=0.03 for both).  These genotypes have not been investigated in 
previous candidate gene association studies, and thus the findings suggest novel 
mechanisms and targets for future research and provide evidence for a contribution of 
sequence variation in antioxidant enzymes to COPD risk. 
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 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by the 
development of airflow obstruction that is not fully reversible, a phenotype that is 
characteristic of chronic bronchitis and emphysema.  At advanced stages, COPD 
commonly progresses to respiratory failure and death, and is a significant cause of 
morbidity as well as the fourth leading cause of mortality in the U.S.(1).  Airflow 
obstruction is reliably and validly measured by spirometry, specifically by the ratio of 
the forced expiratory volume in the first second to the forced vital capacity 
(FEV1/FVC) and by the reduction in percent of the FEV1 value predicted according to 
an individual’s age, height, race, and gender (ppFEV1). Both spirometry parameters 
are used to diagnose and stage COPD (2). Decline in FEV1 occurs naturally with 
aging, but a steeper rate of decline, as observed in susceptible cigarette smokers, is a 
harbinger of the debilitating low lung function that characterizes COPD.   
Current theories of the pathogenesis of COPD posit that an imbalance between 
oxidant burden and antioxidant protection leads to oxidative damage that contributes 
to disease pathogenesis.  Diminished antioxidant defenses, especially among cigarette 
smokers, who are exposed to a high level of oxidants, are hypothesized to contribute 
to tissue changes underlying disease development (3). A minority of smokers develop 
obstructive lung disease(4), consistent with the hypothesis that in some smokers 
compromised antioxidant protection, as a result of genetic variation in antioxidant 
enzyme and/or diets low in antioxidants, contributes to susceptibility. While 
observational studies mainly report positive associations between nutrients with 
antioxidant properties and lung function, with stronger effects in cigarette smokers, 
studies of genes that play a role in antioxidant defenses provide a novel test of the 
susceptibility hypothesis.  
Genetic studies show that lung function is a heritable trait, and heritability 
55 
 
 estimates of FEV1 and the ratio of FEV1/FVC range from 40-90% (5-7). A single gene 
disorder that increases COPD risk, alpha 1-antitrypsin deficiency, has been 
discovered, but it accounts for only about 1 to 2% of cases(8), suggesting the 
importance of additional genes in lung function variability.  Recently completed 
genome-wide association studies of lung function phenotypes (9-11) have identified 
14 genomic regions for further investigation. Well-designed studies of candidate 
genes, specifically of genes encoding antioxidant enzymes,  are important to the 
evidence base, but published studies have several limitations  (as reviewed in (12)).  
The majority of candidate gene studies consider only a few markers and/or genes, and 
thus fail to capture the related and redundant functions within the network of 
antioxidant-related genes.  Also, by definition, such studies focus on a limited subset 
of genes (most prominently, glutathione S-transferases), thus many genes related to 
antioxidant defense are unstudied at the population level (for example, genes of the 
thioredoxin system: thioredoxin, thioredoxin reductase, and peroxiredoxin).  Studies 
of the heritability of lung function provide compelling evidence for a gene-
environment interaction (13-15), specifically a gene by smoking interaction, and a 
recent genome-wide assessment of gene expression in the small airway epithelium and 
genotype in smokers and non-smokers indicates considerable influence of smoking 
parameters modifying the relation between genotype and gene expression (Andrew 
Clark, personal communication). Despite this evidence, many studies do not consider 
gene-environment interactions and/or do not appropriately account for cigarette 
smoking in study design and analysis.  Finally, data on African Americans are limited, 
and most studies with African American participants are underpowered to investigate 
any differences in the effects of genotype on lung phenotype by race.   
We investigated the association of variants in genes encoding antioxidant 
enzymes with the lung function phenotypes ppFEV1 and FEV1/FVC.   As the elderly 
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 are at the greatest risk for reduced lung function associated both with aging and 
smoking, these analyses were conducted in the Health, Aging, and Body Composition 
(Health ABC) Study, a prospective cohort of African American and European 
American seniors. The discovery-based approach explored the relation of all 
genotypes with the two phenotypes, stratified by race, and allowing for differential 
effects of genotype by cigarette smoke exposure and dose. 
 
Methods 
Population 
The Health ABC study cohort comprises 3,075 older men and women (aged 
70-79 at baseline). Health ABC is a random sample of European Americans and all 
African American Medicare-eligible persons residing in ZIP codes from the 
metropolitan areas surrounding Pittsburgh, Pennsylvania and Memphis, Tennessee. 
Eligibility criteria included self-report of: no difficulty walking one-quarter of a mile 
or climbing 10 steps without resting; no difficulty performing basic activities of daily 
living; no use of a cane, walker, crutches or other special equipment to ambulate; no 
history of active treatment for cancer in the prior 3 years; and no plan to move out of 
the area in the subsequent 3 years.   
Exclusion criteria included a low call rate for genotypes, missing outcome 
measurements, or prevalent chronic obstructive pulmonary disease, defined as both 
FEV1 and FEV1/FVC below the population-defined lower limits of normal.  
Exclusions were also made based on quality of spirometry testing for FEV1; 
participants with low quality FVC measurements were additionally excluded from the 
FEV1/FVC analysis.   
Lung Function Outcome 
Spirometry was performed during the clinical visit at study entry using a 
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 horizontal dry rolling seal HF6 Spirometer (Sensor Medics Corporation, Yorba Linda, 
CA) connected to a personal computer.  Tests were conducted in accordance with 
standardized guidelines, as previously reported (16).  PpFEV1 values were calculated 
using prediction equations generated from the Third National Health and Nutrition 
Examination Survey data (17).  When pulmonary function measurements from the 
first clinical visit were not available or not acceptable, the first acceptable spirometry 
data from a subsequent clinical visit (at 4 and 7 years of follow-up) was included, 
provided that the age of the participant at the time of the measurement was within the 
age range of the full sample at the first clinical visit (age 70-79).  The majority (95%) 
of data used in this analysis was from the first clinic visit. 
Selection of SNPs 
Fifty-six genes were identified that are known to affect the balance of 
antioxidants/oxidants and are expressed in lung tissue (Table A.4).  384 SNPs were 
selected with the goal of capturing variation across each gene and its regulatory region 
(2 kb upstream and downstream); further details of analyzed SNPs are presented 
separately (Table A.7).  SNP selection was conducted according to the following order 
of priority: 1. nonsynonymous SNPs, 2. SNPs to provide adequate coverage of genetic 
variation (maximum LDU of 0.9 LDU between SNPs), 3. if genetic variation was 
limited across the gene, SNPs to cover large physical distance across the gene, and 4. 
SNPs in high LD with SNPs of interest to provide redundancy in the event of assay 
failure.  When possible, a minimum of 5 SNPs were selected per gene.  Separate 
consideration was given to European American and African Americans in SNP 
selection to maximize coverage in both populations, given differences in LD structure 
and allele frequencies.  
Genotyping 
DNA for the Health ABC participants was extracted using the Gentra Puregene 
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 DNA Purification Kit (QIAGEN, Valencia, CA) from stored, frozen buffy coat 
originally extracted from 10 ml whole blood.  SNPs were assayed using the Illumina 
Goldengate platform; assays were performed by Johns Hopkins University SNP 
Center, the Center for Inherited Disease Research, under the auspices of the National 
Heart, Lung, and Blood Institute’s Resequencing & Genotyping Service.  Genotyping 
quality was excellent as determined through use of blind duplicates and HapMap 
controls with known genotypes (99.99% and 99.83% reproducibility rates, 
respectively).   
Data Analysis 
Linear models were used to evaluate the association between SNPs and lung function 
phenotype.  All models included adjustment for study site, age, height, and gender 
(18). SNPs were coded as additive, recessive, dominant, or heterozygote advantage, 
depending on the pattern of association observed and a sufficient number of 
participants in subgroups of genotype and smoking parameters. SNPs with a minor 
allele frequency <1% were excluded from the analyses (n=29 in European American; 
n=1 in African Americans). 
Smoking status was represented as former and current smokers, separately, 
compared to never smokers (defined as self-report of less than 100 cigarettes smoked 
throughout lifetime).  Smoking dose was considered as packyears, and categorized as 
high (above the median, 27 packyears), low (1-27 packyears), or no smoking history.  
Modification of the SNP-outcome association by smoking was assessed through 
product terms of each SNP with both smoking dose and smoking status.  
As a first approach, regression coefficients with a nominal p<0.002 were 
selected as the most statistically significant ‘hits’ or findings. In further analyses, 
correction for multiple comparisons was conducted as follows: within an analysis, p-
values were adjusted using the false discovery rate with a q-value of 0.05 (19); p-
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values were then multiplied by the number of analyses of that phenotype in order to 
adjust for correlated outcomes.  For example, the false discovery rate adjustment was 
applied to all of the results for European Americans testing the interaction between 
SNPs and smoking status in the prediction of ppFEV1; these p-values were then 
multiplied by 3 to account for the number of analyses conducted on this outcome 
(main effects of SNP on ppFEV1, interaction between SNPs and smoking status on 
ppFEV1, and interaction between SNPs and smoking dose on ppFEV1). Both 
approaches, nominal p<0.002 and multiple comparison adjusted findings are presented 
in results. R2 values between SNPs were determined using Haploview (20). All data 
analyses were conducted using SAS v 9.1 (SAS, Cary, NC). 
 
Results 
Genotype data were available for 2,762 participants.  After exclusion for 
missing smoking information (n=5), 2,387 (86%) participants had an acceptable FEV1 
measurement and were included in the ppFEV1 analysis, and 2,190 (79%) had 
acceptable FVC measurements and were included in the FEV1/FVC analysis (Table 
4.1). The ppFEV1 phenotype had a mean of 97% in this population, with a range of 
36% to 181% and a standard deviation of 19%. The ratio of FEV1/FVC phenotype 
(calculated as FEV1/FVC * 100) had a mean of 75, with a range of 34 to 98 and a 
standard deviation of 6.   
The 35 most statistically significant SNPs (nominal p<0.002) reveal more 
effects in African Americans, and only 10 (29%) of the top hits were in European 
Americans.  Nine of the most statistically significant SNPs (26%) were associated 
with the ppFEV1 phenotype.  Only 7 of the associations (20%) were in models 
estimating the main effect of the SNP on lung function phenotype (Table 4.2), and the 
majority of statistically significant associations were in models of effect modification 
  
 
 
 
Table 4.1:  Characteristics of Health, Aging, and Body Composition Study Participants Included in Analysesa 
 
 % Predicted FEV1 FEV1/FVC 
 African 
Americans 
n=972 
European 
Americans 
n=1415 
African 
Americans 
n=855 
European 
Americans 
n=1335 
Age, years 73.3 (2.9) 73.7 (2.8) 73.3 (2.9) 73.7 (2.9) 
Women (%) 569 (58.5) 682 (48.2) 481 (56.3) 629 (47.1) 
Memphis, TN site (%)b 434 (44.7) 674 (47.6) 375 (43.9) 638 (47.8) 
Former Smokers (%) 390 (40.2) 707 (50.0) 350 (41.0) 668 (50.1) 
Current Smokers (%) 139 (14.3) 75 (5.3) 124 (14.5) 71 (5.3) 
Packyears  27.4 (23.9) 34.3 (30.9) 27.7 (23.9) 34.2 (30.8) 
FEV1, ml     
      Women 1724 (367) 1946 (379) 1729 (368) 1959 (376) 
      Men 2369 (517) 2759 (531) 2382 (511) 2767 (533) 
PpFEV1 99.4 (21.4) 95.5 (16.9) 99.8 (21.3) 95.9 (16.9) 
FEV1/FVC 77.0 (7.4) 75.9 (6.1) 76.0 (6.6) 75.1 (5.8) 
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a Mean (SD) listed unless otherwise indicated. 
b vs. Pittsburgh, PA site.  
 
 
 
 
  
 
 
 
Table 4.2: Main Effects, Most Statistically Significant Resultsa 
Population Outcome SNPb Gene P-valuec Key Findings 
European ppFEV1 None    
Americans FEV1/FVC None    
      
African ppFEV1 Rs535537 GSTM4  0.0007 AA 14% higher, AG 4% lower than GGd 
Americans  Rs627365 GSTM4  0.001 AA 43% higher, AG 5.5% higher than GG 
  Rs7768 PRDX3 0.001 CC 5% lower than CG/GG 
 FEV1/FVC Rs2284650 GCLC 0.002 GG ratio 9 lower than GA/AA 
  Rs7294985 mGST1  0.0004 AA/AG ratio 2.3 lower than GG 
  Rs7768 PRDX3  0.001 CC 2% lower than CG/GG 
  Rs7068937 PRDX3  0.002 AA/AG  1.4 higher ratio than GG 
aAll results with nominal p-value <0.002 62
bSNPs in bold remained statistically significant after adjustment for multiple comparisons 
cNominal p-values shown 
dParticipants with the homozygous variant genotype had 14% higher ppFEV1 than participants who were homozygous for  
the wild type allele. Heterozygotes had a 4% lower ppFEV1 than wild type homozygotes. 
 
 
 
 of the SNP by cigarette smoking (Table 4.3). Effect sizes ranged from 4% to 35% for 
the ppFEV1 phenotype, and from 1.4 to 15 units for the FEV1/FVC ratio phenotype.  
Together, the most statistically significant SNPs associated with the main effects 
accounted for 3% of the variability in the ppFEV1 phenotype and 4% of the variability 
in the FEV1/FVC ratio phenotype among African Americans (no main effect SNPs 
were identified in European Americans).  SNP-smoking interactions accounted for 3% 
(both European and African Americans) of the variability in the ppFEV1 phenotype, 
and 5% and 17% (European and African Americans, respectively) of the variability in 
the FEV1/FVC ratio phenotype. 
SNPs in genes encoding peroxiredoxins (PRDXs) were associated with 
ppFEV1 and FEV1/FVC in both African Americans and European Americans.  An 
interaction between rs9787810 (PRDX5) and both smoking status and smoking dose 
was highly statistically significant in models of both lung phenotypes in European 
Americans.   Although slightly less statistically significant (and not shown), the 
interactions between another SNP in PRDX5 (rs1047206) and both smoking status and 
dose were associated with ppFEV1 in African Americans (p=0.004 for both). In 
African Americans, SNPs in PRDX3 (rs7768 and rs7068937) were associated with 
lung phenotypes, and a third SNP (rs1119881; R2 for all 3 SNPs <0.8) had a similar 
though less statistically significant association (p=0.004).  A SNP in PRDX4 
(rs528960) modified the effect of smoking status on the ratio of FEV1/FVC in African 
Americans.  Overall, 6 of the 19 SNPs in PRDX3, PRDX4, and PRDX5 were 
associated with lung outcomes at p<0.005. 
The association of SNPs in isocitrate dehydrogenase (IDH) genes with lung 
function phenotypes comprised some of the most statistically significant findings.  
Three IDH SNPs in European Americans (2 in LD) and 5 IDH SNPs in African 
Americans (none in LD) showed evidence of interaction with cigarette smoke in
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 Table 4.3: Smoking Interactions, Most Statistically Significant Resultsa 
Population Outcome Interactionb Gene P-valuec Key Findingsd 
European ppFEV1 Rs17674205*Status IDH3A 0.0008 FS GG 39% higher than FS GA/AA (no CS GG)g 
Americans  rs9787810* Status PRDX5 0.0002 FS AA/AG 12.7% higher than FS GG 
  Rs6413428*Status SEPP1 0.001 CS GG 43% higher than CS GA/AA; FS GG 14% higher than  
FS GA/AA 
  Rs9787810*Dose PRDX5 0.002 FS AA/AG high dose 11%, low dose  8.5% higher than FS GG 
 FEV1/FVC Rs11631100*Statuse IDH3A  0.0009 CS AA 12.7% higher than CS AG/GG 
  Rs3816253* Statuse IDH3A  0.001 CS GG 12.5% higher than CS GA/AA 
  Rs9787810* Status PRDX5  0.0002 FS AA/AG ratio 4.5 higher than FS GG 
  Rs2066511*Dose GCLC 0.0006 CS AG ratio 3 higher (low dose) than CS AA/GG 
  Rs3740466*Dose GSTO2 0.002 CS AG ratio 4.6 and 2.3 lower (high/low dose) than CS AA/GG 
  Rs9787810*Dose PRDX5 0.002 FS AA/AG ratio 4 higher (high and low dose) than FS GG 
African  ppFEV1 Rs1002149*Status GSR 0.0006 FS AC 19.5% higher than FS AA/CC  
Americans  Rs4236107*Status GSTA5 0.002 FS GA 9% higher than FS GG/AA 
 FEV1/FVC Rs8030346*Status IDH2  0.0009 CS GG ratio 1.2 lower than CS GA/AA 
  Rs6107100*Status IDH3B  0.000002 CS AC ratio 13 higher than CS AA/CC 
  Rs6037255*Status IDH3B 0.002 CS AA/AC ratio 13 higher than CS CC 
  Rs528960*Status PRDX4 0.002 CS GA ratio 9 higher than CS GG/AA 
  Rs2042286*Status SEPW1  0.0002 CS AA/AG ratio 15 higher than CS GG 
  Rs1139793*Status TXNRD2 0.0007 CS AA/AG ratio 2.5 lower than CS GG 
  Rs10801174*Dosef GLRX2 0.0001 CS TT/TA ratio 10 higher (high and low dose) than CS AA 
  Rs7547615*Dosef GLRX2 0.00009 CS GG/GA ratio 10 higher (high and low dose) than CS AA  
  Rs2250192*Dose GSR 0.0005 CS AA ratio 11 lower than CS CC 
  Rs2281594*Dose GSTA3 0.002 CS CC ratio 11.5 lower (low dose) than CS CG/GG 
  Rs8028234*Dose IDH2 0.001 CS TT/TA ratio 7/13 (high/low dose) higher than CS AA 
  Rs17674205*Dose IDH3A 0.001 CS GG/GA ratio 13 higher (high dose) than CS AA 
  Rs6107100*Dose IDH3B  0.00001 CS AC ratio 11/10 (high/low dose) higher than CS AA/CC 
  Rs2297765*Dose mGST3 0.001 CS GG ratio 14 lower than CS GA/AA 
  Rs2042286*Dose SEPW1  0.001 CS AA/AG ratio 12 higher (high and low dose) than CS GG 
  Rs8139906*Dose TXN2 0.001 CS CC/CG ratio 12 higher (high) than GG; FS CC/CG ratio 2.7  
lower than FS GG 
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aAll results p<0.002, bSNPs in bold statistically significant after multiple comparison adjustments,cNominal p-values, dAbbreviations: CS (current smokers); 
FS (former smokers), eLD observed between SNPs (R2=0.92) fLD observed between SNPs (R2=0.99) g FS homozygous for the variant genotype (GG) had a 
39% higher ppFEV1 than FS who were heterozygous (GA) or homozygous for the major allele (AA).  No CS were homozygous for the variant genotype. 
 
 
 predicting lung phenotypes.  The most statistically significant finding in these analyses 
was the interaction of rs6107100 (IDH3B) and smoking status in relation to the 
FEV1/FVC ratio (p=2 x 10-6).  Ten additional associations between SNPs in IDH 
genes and lung phenotypes were statistically significant at p<0.005 (data not shown). 
SNPs in genes with disulfide reductase activity were also prominent among the most 
statistically significant findings in African Americans, and interactions between 
smoking and SNPs in GSR, GLRX2, and TXNRD2 were identified. 
After correction for multiple comparisons, 4 results remained statistically 
significant (indicated in bold in Table 4.3).  The IDH3B SNP (rs6107100) modified 
the effect of smoking status and dose on the ratio of FEV1/FVC in African Americans 
(padj=0.002 and 0.01 for SNP by smoking status and dose interaction terms, 
respectively).  Two SNPs in GLRX2 (rs10801174 and rs7547615, in strong LD) also 
modified the effect of smoking dose on the ratio of FEV1/FVC in African Americans 
(padj=0.03 for both).  
Some of the most statistically significant results were excluded from 
presentation here due to small numbers of participants (n<5) in the genotype/smoking 
subgroup with the strongest association.  Despite the reduced confidence in these 
results, the strength of the associations observed (some of which remained statistically 
significant after correction for multiple comparisons) may suggest a biologically 
interesting relation.  These results are summarized separately (Table A.8).  Briefly, 
SNPs in genes associated with glutathione synthesis (GCLC and GGT), with 
peroxidase activity (GPX2, GPX3, PRDX6), and encoding glutathione S-transferases 
(GSTA3, GSTA5, GSTZ1, and mGST2) were associated with the lung function 
phenotypes studied.    
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 Discussion 
 This study was designed to evaluate the hypothesis that sequence variation in 
genes encoding antioxidant enzymes, which are expected to alter antioxidant defenses, 
contributes to COPD susceptibility, especially among cigarette smokers.  The findings 
reported here support this hypothesis and provide important direction for future 
research. 
 SNPs in the peroxiredoxin family of genes were prominent in the list of most 
statistically significant associations.  Interactions between SNPs in PRDX5 and 
smoking parameters were associated with ppFEV1 in both African Americans and 
European Americans and with FEV1/FVC in European Americans.  For rs9787810, a 
PRDX5 SNP appeared 4 times in the top results, and both the size of the effect (about 
12% higher on ppFEV1 and 4 units higher on ratio of FEV1/FVC in the AA/AG 
genotype groups vs. wildtype) and the prevalence of the variant genotypes in the 
European ancestry group (54%) suggest that this finding is important in terms of 
population attributable risk. However, these particular genotypes are less prevalent in 
African Americans (13%), and small numbers in genotype/smoking subgroups limited 
analyses. In African Americans, SNPs in another peroxiredoxin gene, PRDX3 (rs7768, 
rs11198811, rs7068937), were associated with moderate effect sizes (5% and 4% 
lower ppFEV1, and 1.4 units higher ratio, respectively, with the variant genotypes as 
represented in Table 4.2), for genotypes that are relatively common (21%, 23%, and 
33%), suggesting that these associations also are meaningful in terms of population 
attributable risks.   
Peroxiredoxins, also called thioredoxin reductases, are a family of peroxidases 
that use the reducing power of thioredoxin (with the exception of PRDX6, which uses 
glutathione).  Although, this is the first study of genetic variants in these genes and 
lung phenotypes, several prior microarray studies provide relevant context for these 
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 results.  Both PRDX3 and PRDX5 were downregulated in smokers compared to never 
smokers (21).  In PRDX3 knockout mice, excessive production of reactive oxygen 
species (ROS) from macrophages was observed after exposure to lipopolysaccharide, 
an inflammatory agent from gram-negative bacteria (22).  Clearly further study of 
peroxiredoxins and COPD-related lung outcomes is needed. 
Members of the isocitrate dehydrogenase gene family (IDHs) were also among 
the most statistically significant associations, and SNPs in these genes interacted with 
smoking to predict lung phenotypes in both African Americans and European 
Americans.  The effect sizes for SNPs in these genes were large, and differences 
between the variant and reference genotypes range from 13 to 39% higher ppFEV1 for 
associations with IDH3A, and differences of over 10 units in the ratio of FEV1/FVC 
for IDH3A, IDH3B, and IDH2 (with the exception of an inverse association for the 
interaction between smoking status and rs8030346 on FEV1/FVC).  The majority of 
these SNPs are common, variant genotype prevalence ranges from 15 to 63% (only 2 
SNPs have a prevalence of < 10% [rs8030346 (IDH2) and rs17674205 (IDH3A)]), 
making the potential impact on lung function outcomes among smokers of 
considerable interest.  While these genes are relatively unstudied at the population 
level as contributors to antioxidant defenses, the role they play in supplying the 
reducing equivalents for the antioxidant activity of the many members of the 
glutathione and thioredoxin system could be pivotal in determining cellular redox 
balance.  In rats, IDH activity and protein expression was age-dependent (23), a 
finding of interest in relation to the associations reported here for phenotypes related 
to the aging of the lung.  In fibroblasts, decreased expression of IDHs led to higher 
lipid peroxidation, oxidative DNA damage, intracellular peroxide generation, and 
increased senescence, indicating an important regulatory role for these genes in the 
defense against oxidative stress (24).   
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 The SNPs identified in our top results, and their interactions with smoking 
parameters, accounted for a relatively large proportion of the variability observed in 
these phenotypes.  The four demographic variables, age, height, gender, and study site 
together explained 5% and 14% (European and African Americans, respectively) of 
the ppFEV1 phenotype, and 2% and 3% (European and African Americans, 
respectively) of the FEV1/FVC phenotype.  Smoking variables explained an additional 
4-7 % of both phenotypes in both European and African Americans.  In the context of 
these known predictors of lung function, the 3-4% of variability associated with SNPs 
in main effect models and 3-17% of variability associated with SNP-smoking 
interactions provide compelling support for a role of these variants in predicting lung 
function. 
None of the actual SNPs in our top results have been investigated in published 
association studies of lung function, and only 2 previous association studies 
investigated other markers in genes represented in our top results.  The variant 
genotype of a SNP in a glutathione synthesis gene, GCLC, was associated with an 
increase in COPD risk in a Chinese population [OR 1.8 (95% CI: 1.0, 3.3)](25).  This 
SNP (rs17883901) was included in our analyses, but no association was observed.  
The variant allele has a higher prevalence among Asians (13%) than among African 
Americans (1%) or Europeans (6%), suggesting a potential reason for this 
discrepancy.  SNPs in a glutathione S-transferase, mGST1 (rs11875, rs2160512, 
rs2239675, and rs2287152), were not associated with ppFEV1 in European American 
emphysema patients (26).  None of these SNPs were included in our analyses, nor 
were they in LD with the SNP in this gene which we found associated with lung 
function (rs7294985).  SNPs included in this analysis were in LD with the previously 
investigated SNPs, and agreed with the null findings.  
In the list of most statistically significant findings (nominal p<0.002), a 
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 striking 50% of genes, comprising 66% of results, encode enzymes found in 
mitochondria.  The mitochondrial genes include all of the IDH genes (IDH3A, IDH3B, 
and IDH2) and 2 of the 3 PRDX genes (PRDX3, and PRDX5) in the most statistically 
significant results.  To date, there are no studies of the role of mitochondrial function 
in relation to lung function at the population level, but results from basic science 
studies provide a useful context for interpretation.  A recent series of experiments 
addressed the effect of cigarette smoke on lung epithelial cells.  While systemic 
increases in biomarkers of oxidative stress are observed with smoking, the high 
concentration of reactive oxygen species (ROS) in cigarette smoke are in the gaseous 
phase; these components likely assault the lining fluid and plasma membranes of 
epithelial cells, but cannot enter cells directly, which leaves the mechanism by which 
they contribute to systemic oxidative stress unclear.  A recent paper suggests that 
lipophilic compounds in cigarette smoke cross through the plasma membrane and 
induce mitochondrial overproduction of ROS, which would be expected, in turn, to 
increase systemic (and local) oxidative stress(27).  In studies of mouse embryonic 
fibroblasts, oxidizing extracellular conditions induce mitochondrial overproduction of 
ROS, signaling an antioxidant response (through nuclear factor (erythroid-derived 2)-
like 2, Nrf2).  Embryonic fibroblasts from transgenic mice over-expressing TXNRD2 
produced less intracellular ROS in oxidizing extracellular conditions, resulting in 
diminished Nrf2-regulated antioxidant gene expression (28).  Also of interest, 
particulate matter, another inhalant associated with lung function decrements, induces 
mitochondrial oxidant overproduction, which leads to the alveolar epithelial cell 
apoptosis associated with this exposure.  Overexpression of the gene encoding a 
cytoplasmic antioxidant enzyme (SOD1) prevented the excess ROS generation and 
subsequent cell death (29).  Taken together, these results suggest a key role for 
mitochondria and mitochondrial antioxidant enzymes in the lung and systemic 
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 response to cigarette smoke exposure.  Specifically, the lipophilic portion of cigarette 
smoke and the oxidizing extracellular environment (the epithelial lining fluid after 
depletion of antioxidants resulting from direct contact with ROS in cigarette smoke) 
may induce an excess production of ROS in the mitochondria; any variability in 
mitochondrial antioxidant enzyme expression or function as a result of sequence 
variation, then, would have significant effects on the oxidative burden in the lungs 
(and beyond). 
  A larger proportion of statistically significant results were consistently 
observed in African Americans compared to European Americans.  Potential 
explanations for this include the following: different distribution of the phenotype in 
the two populations, different exposure to cigarette smoking, and differences in 
genetic variation in the studied genes.  Mean ppFEV1 was higher in African 
Americans, and the standard deviation was larger compared to European Americans; 
the mean FEV1/FVC ratio was also somewhat higher in African Americans, and the 
standard deviation was greater (Table 4.1).  More variability in the phenotype could 
improve the ability to distinguish different effects by genotype, but it is unlikely that 
these small differences fully account for the dramatic differences observed by race.  A 
much higher proportion of African Americans were current smokers (14% compared 
to 5% in European Americans), although their smoking history suggests a lower 
lifetime dose (27 vs. 34 packyears in African vs. European Americans, respectively).  
The higher proportion of participants who are currently smoke-exposed may indicate a 
greater burden of oxidative stress on these antioxidant enzymes, making the effects of 
perturbations to these enzymes (via genetic variants) more apparent. Finally, as is 
well-established, patterns of linkage disequilibrium are very different between African 
Americans and European Americans as a result of migratory history of populations.  
The reduced correlations between SNPs in African Americans functionally equates to 
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 a greater level of variation tested.  This increase in genetic variation tested could 
reasonably enhance the ability to detect associations.  Only one SNP was identified 
among the most statistically significant results in both African Americans and 
European American: interactions between smoking parameters and rs1764205 
(IDH3A) were associated with lung outcomes; these results were in a consistent 
direction, with large increases in lung function observed in cigarette smokers with 
variant genotypes.  Despite the lack of overlap, however, the same functional gene 
groups were prominent in both African American and European American subgroups 
(peroxidase activity, supply of reducing equivalents, and disulfide reductases).    
There were consistently more statistically significant associations with the ratio 
of FEV1/FVC phenotype as compared to ppFEV1.  As exemplified by the role of the 
ratio in diagnosing COPD, reductions in the ratio are a clear indicator of airflow 
obstruction.  Using an “adjustment” of the FEV1 value for FVC (via calculation of the 
ratio) essentially isolates the factors that are associated with obstruction and not with 
overall lung capacity.   
Looking separately for the interactions between smoking status and dose 
allowed for some inference regarding the potential role of an enzyme in a smoking 
challenge.   For instance, interactions were observed for SNPs in IDH genes with both 
smoking status and smoking dose; this result suggests that these genes are broadly 
important for both smoke exposure and increasing levels of smoking.  SNPs in GSR, 
however, were only observed to interact with smoking dose, suggesting a differential 
effect for varying levels of exposure.  
Several strengths of this work deserve mention.  First, these analyses were 
conducted in a large, epidemiological cohort, a study design which is uniquely suited 
to investigate the genetics of complex diseases, especially when considering gene-
environment interactions (30,31).  Other aspects of the design of the cohort were 
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 advantageous to this work: the advanced age of the participants, which meant greater 
variability in the outcome as a result of both aging and environmental exposure; 
careful characterization of smoking history; a sufficiently large proportion of African 
Americans to justify a stratified analysis (a relatively undescribed population with 
respect to this research question); and high quality spirometry.   
 Currently, researchers are turning to genome-wide association studies (GWAs) 
to discover novel gene regions of interest in relation to a particular phenotype.  The 
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
consortium recently completed a meta-analysis of GWAS of FEV1 and FEV1/FVC in 
over 20,000 participants in 4 epidemiologic cohort studies, including Atherosclerosis 
Risk in Communities, Cardiovascular Health Study, Framingham Heart Study, and the 
Rotterdam Study was recently completed (32).  None of the genes in our most 
statistically significant results list (nor any of our studied genes) appeared in the top 
2000 hits in the CHARGE study.  According to a recent study, it is unlikely that this 
discrepancy is a result of the failure of the GWAS to appropriately capture the genetic 
variation present in our studied genes (33).  Although a replication of the Health ABC 
findings by the CHARGE cohorts would strengthen the finding, an absence of 
replication may be explained by several scenarios.  The CHARGE GWAS considered 
a linear, additive coding of SNPs, such that 2 copies of an allele were expected to have 
an effect size that was approximately double the effect of a single copy of the allele, 
and a single parameter estimate was used to describe this relation (thus, regression 
coefficients and p values test this additive effect).    In the Health ABC analyses, the 
best coding for each SNP (on the basis of strength of association with outcome) was 
used, and additive coding was modeled as a set of dummy variables to avoid 
assumptions about linearity in the genotype—phenotype association.  Given that SNPs 
are known to affect disease risk in a variety of ways (i.e. dominant, recessive, 
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 heterozygote advantage, additive/multiplicative), the lack of replication may be 
explained by a difference in coding between CHARGE and Health ABC studies. 
Although the CHARGE GWAS stratified by smoke exposure (with never smokers 
analyzed separately from current and former smokers), there was no formal test of 
gene-environment interactions (for instance, with a product term between the SNP and 
smoking parameter), another difference between CHARGE and Health ABC analysis 
approaches.   
When the models producing the 35 most statistically significant results in the 
Health ABC analyses were re-analyzed using the coding and stratification strategies 
described in the CHARGE GWAS, only 2 of the 35 SNPs remained associated with 
the outcome at the level of statistical significance used to define the set of top hits 
(p<0.002).  Only one of these results (Rs6037255 in the prediction of FEV1/FVC 
among smokers) would have met the CHARGE GWAS criteria for inclusion among 
the top 2000 hits for this outcome; seven of the results reported among the most 
statistically significant results in the Health ABC analysis as presented met this 
criteria.  Clearly, decisions regarding coding of alleles and modeling of gene-
environment interactions are of vital importance in genetic association studies.   
Another notable difference between the Health ABC study and the CHARGE 
GWAS meta-analysis is the demography of the populations studied.  The Health ABC 
population was about 40% Black, while all of the participants in the CHARGE 
analyses were of European ancestry (an important difference considering the 
proportionately higher number of findings among Blacks in the Health ABC results).  
Also, the mean age of the participants in the CHARGE GWAS was considerably 
lower (58 vs 73 years); a smaller proportion of these populations may be experiencing 
the age-related increases in susceptibility to low lung function.  Consistent with this 
hypothesis, the mean FEV1 was higher in CHARGE (2,807 vs 2,215 ml), a difference 
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 that could not be attributed to differences in gender distribution (mean proportion of 
women 55 and 52% in CHARGE and Health ABC, respectively).  Population 
characteristics are also of vital importance in drawing comparisons between genetic 
epidemiology studies. 
Although overlap exists in this project and the CHARGE GWAS analysis, these 
differences above highlight the unique contribution of the Health ABC project in 
addressing the question of genetic factors in COPD susceptibility: motivating 
candidate gene studies with biological hypotheses allowed for a more focused 
interrogation of the role of these genes and consideration of appropriate environmental 
factors expected to interact with them.   
 In summary, this analysis provides evidence for a role of genetic variation in 
antioxidant enzymes and lung function outcomes important in predicting risk of 
COPD and the trajectory of aging.  This work complements research conducted on 
dietary determinants of antioxidant capacity in that the genetic determinants of 
antioxidant capacity are not anticipated to be associated with lifestyle factors, and so 
are not subject to the residual confounding concerns that limit the interpretation of 
studies of diet.  Of particular importance in these results are SNPs encoding members 
of the peroxiredoxin and isocitrate dehydrogenase gene families, suggesting that the 
function of peroxidases dependent on thioredoxin and the overall production of 
reducing equivalents are important in predicting lung outcomes, especially in the 
presence of oxidant challenge, and interventions that support these systems may yield 
beneficial results.   
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CHAPTER 5 
CONCLUSION 
 
The three projects comprising this dissertation focus on the role of antioxidant 
defenses in maintaining lung health and in avoiding chronic obstructive pulmonary 
disease (COPD), particularly with oxidative stress challenge.  Specifically, the 
overarching goal of this research is to understand whether variability in antioxidant 
defenses contributes to the susceptibility to COPD and lower lung function, especially 
in the presence of cigarette smoke. There are at least three determinants of the balance 
between oxidants and antioxidants in the lung: environmental oxidant exposures 
(exogenous sources of oxidants such as smoking, occupation, air pollution), and 
endogenous capacity to offset damage by oxidants as influenced by dietary intake of 
nutrients with antioxidant properties, and by genetic variation affecting antioxidant-
related enzymes.  The projects described herein address the roles of environment, 
nutrition and genetics in relation to lung health.  
The association between smoking and lung function is well-established and the 
central role of cigarette smoking has been carefully considered in the three projects.  
Although observational studies reported an association between low dietary 
antioxidant intake and decreased pulmonary function/higher risk of COPD, the 
majority of prior research was cross-sectional and there were no studies of elderly 
populations, a striking lack in the evidence base given that older populations face a 
greater risk of steep declines in lung function.   Thus, the first project in this 
dissertation was a prospective cohort study of an elderly population.  Much less 
evidence existed on the association between sequence variation in genes encoding 
78 
 
 antioxidant-related enzymes and lung function.  As such, before designing a study to 
investigate this association, a systematic overview was completed to evaluate the 
published studies investigating genetic factors influencing antioxidant capacity and 
COPD/COPD-related lung outcomes.  The systematic overview guided study design 
and motivated gene selection for the third project, which investigated the association 
between sequence variants in antioxidant enzymes and lung function in an elderly 
cohort.  The conclusions from these projects and their contribution to answering the 
overall research question are described below. 
 
Dietary Antioxidants and Lung Function Decline: the Health Aging and Body 
Composition Study 
 
In cigarette smokers a higher dietary intake of a broad range of nutrients with 
antioxidant properties was associated with a shallower rate of decline in lung function 
over 4 years of follow-up.  Thus, the major finding from this longitudinal study of 
well-functioning older adults supports the hypothesis that dietary antioxidant intake is 
a modifiable factor that affects the rate of decline in FEV1.  Among current smokers, 
consumption of diets that were higher in vitamin C, vitamin E, β-carotene, and fruits 
and vegetables were associated with biologically meaningful differences in lung 
function trajectory compared to consuming diets low in these nutrients.  Because the 
study collected dietary intake data at only one time during the follow-up of 9 years, 
the analysis explored whether findings were stronger when focusing on the time 
period surrounding this single measurement. The relation of dietary intake to lung 
function decline was strongest in participants who were current smokers at study 
baseline and had quit by their 4-year clinical visit: those participants with high intakes 
of vitamin E, β-carotene, vitamin C and fruit and vegetables had 83, 73, 52 and 32 
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 ml/year lower rate of decline in FEV1, respectively, compared to participants with low 
intake (high and low refer to the 90th and 10th percentile points, respectively, for the 
purposes of illustrating the associations, although underlying statistical models are 
continuous).  All associations were diluted in models of antioxidant intake and 9-year 
rate of decline; a likely explanation for this dilution is that a single, early assessment 
of dietary intake was primarily informative of concurrent oxidant/antioxidant balance 
and proximal rate of decline. 
The strong interactions seen between oxidant exposure and antioxidant intake 
provide support for the hypothesis that antioxidant capacity modifies the lung’s 
response to smoke exposure.  In the prospective cohort study potentially confounding 
variables were adjusted in statistical models, but efforts to fully adjust for all sources 
of confounding are ultimately imperfect, thus other approaches to address the research 
questions were pursued to strengthen the evidence relative to causal inference.   
 
Genetic Variation and Gene Expression in Antioxidant-Related Enzymes and Risk of 
COPD: A Systematic Review 
To address the limitations inherent in observational studies of antioxidant 
intake and lung function, the question of endogenous antioxidant capacity as a 
modifier of the association between smoke exposure and lung function was 
investigated with a genetic approach.  Genetic factors, like dietary antioxidant intake, 
can affect the balance between oxidants and antioxidants in the lung, but studies of 
genetic variation are less likely to be affected by confounding bias.  A systematic 
overview of prior studies of genes encoding antioxidant enzymes in relation to COPD 
and COPD-related lung phenotypes was conducted to understand the state of the field, 
to identify gaps in evidence, and to establish the baseline for a new study of genetic 
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 variation in genes encoding antioxidant enzymes and COPD-related lung phenotypes.  
The systematic overview summarized studies of sequence variation and studies of 
gene expression to provide a more complete understanding of the full role of genetic 
factors in the pathophysiology of lung disease. At the time the systematic review was 
published, only one genome-wide association study had been conducted, and the 
majority of studies in the literature were candidate gene association studies, family-
based studies, or micro-array (small sample) studies.  
The systematic review included all studies of relevant lung outcomes and 
enzymes of known importance in maintaining redox balance in the lungs, including 
glutathione metabolism, the thioredoxin system, superoxide dismutases, and catalase.  
A total of 29 genetic association and 14 comparative gene expression studies met the 
inclusion criteria.  There were very few instances where the evidence was sufficient to 
justify summary statements of effect for a particular gene, however the paper provided 
the first critical evaluation of research in this area, and identified targets for future 
studies.   
Several methodological issues were highlighted by the systematic overview.  
Given the important role of smoking in COPD etiology and intraindividual variation in 
the response to smoke exposure, careful consideration of smoking parameters during 
study design and analysis are vital to uncovering gene-disease associations.  Gene-
smoking interactions were rarely tested in published papers (although analyses were 
sometimes limited to smoke-exposed participants) and a description of the smoking 
status of participants was occasionally omitted.  The systematic overview also 
revealed that a limited number of genes, and SNPs within those genes, have been 
evaluated for an association with disease risk, an important finding considering the 
broad, interrelated network of antioxidant enzymes in the lungs.  For instance, 24 
published association studies studied genes encoding glutathione s-Transferases 
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 (GSTs), but no association studies studied genes associated with thioredoxin 
metabolism.  Furthermore, in the association studies studying GSTs, only 3 genes (out 
of 18 total GST genes) and 4 variants were evaluated, comprising a limited study of 
the gene family. The limited consideration of environmental interactions and the 
scarcity of research on all but a few SNPs in a handful of genes, there were serious 
limitations to any inferences about the role of sequence variation in antioxidant 
enzymes in relation to disease risk. 
 
Genetic Variation in Antioxidant Enzymes and Lung Function in the Health, Aging, 
and Body Composition (Health ABC) Study 
With the conclusions from the systematic review in hand, a new study was 
designed to investigate whether the role of genetic variation in antioxidant enzymes in 
lung phenotypes.  Two spirometry parameters were evaluated for these analyses: the 
ratio between the forced expiratory volume in the 1st second and the forced vital 
capacity (FVC) (thus, the FEV1/FVC), and the percent achieved of the FEV1 value that 
was predicted for that participant based on height, race, gender, and age (% predicted 
FEV1).  The ratio and the % predicted FEV1 are used to diagnose and stage COPD. 
The ratio identifies decreases in FEV1 in relation to FVC, which is a hallmark of 
airflow obstruction.  The % predicted FEV1 is used in conjunction with the FEV1/FVC 
ratio as a method of grading severity of airflow obstruction.  The quantitative markers 
of lung phenotype were preferred over a disease-based approach for several reasons: 
quantitative measures of lung phenotype increased the power to detect associations, 
variability in these outcomes may have functional significance in an elderly population 
beyond COPD diagnosis, analyses with these measures may be more robust than 
analyses of COPD diagnosis given debates among experts regarding the most 
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 appropriate thresholds for diagnosis, and, importantly,  these measures are available at 
high quality for a large proportion of the Health, Aging, and Body Composition 
cohort.  As these measures underlie COPD diagnosis, they are considered as robust 
predictors of disease risk, and indeed in elderly populations spirometry also predicts 
all-cause mortality(1).     
To address a gap in the current literature, this study was designed to evaluate 
the entire network of enzymes of known importance in redox balance that are 
expressed in the lung.  Fifty-six genes were selected, the majority of which had never 
been considered in an association study of COPD-related lung outcomes, but, given 
their function, may have an important role in determining an individual’s response to 
the oxidative assault of cigarette smoking.  As the interest was in identifying genes of 
importance in disease risk, markers were selected to fully represent the genes and their 
regulatory regions.  Although preference was given to inclusion of SNPs that had 
previously been investigated or with known function in relation to these outcomes, the 
evidence base was such that this constituted only 2% of SNPs selected. 
 The results from these analyses are novel: of the genes represented among the 
most statistically significant SNPs, only 1 gene had been previously evaluated in an 
association study (GCLC), suggesting the benefits of taking a network approach.  A 
large proportion of the genes (64%) represented in the most statistically significant 
results produce mitochondrial enzymes, suggesting new hypotheses about the 
importance of this cellular compartment in lung function phenotypes and COPD risk. 
 Currently, researchers are turning to genome-wide association studies (GWAs) 
to discover novel gene regions of interest in relation to a particular phenotype.  The 
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
consortium recently completed a meta-analysis of GWAS of FEV1 and FEV1/FVC in 
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 over 20,000 participants in 4 epidemiologic cohort studies, including Atherosclerosis 
Risk in Communities, Cardiovascular Health Study, Framingham Heart Study, and the 
Rotterdam Study(2).  Comparisons between the Health ABC results and the CHARGE 
results are of interest.  None of the genes in our most statistically significant results list 
(nor any of our studied genes) appeared in the top 2000 hits in the CHARGE study.  
According to a recent study, it is unlikely that this discrepancy is a result of the failure 
of the GWAs to appropriately capture the genetic variation present in our studied 
genes (3).  Although a replication of the Health ABC findings by the CHARGE 
cohorts would strengthen the finding, an absence of replication may be explained by 
several scenarios.  The CHARGE GWAS considered a linear, additive coding of 
SNPs, such that 2 copies of an allele were expected to have an effect size that was 
approximately double the effect of a single copy of the allele, and a single parameter 
estimate was used to describe this relationship (thus, regression coefficients and p 
values test this additive effect).    In the Health ABC analyses, the best coding for each 
SNP (on the basis of strength of association with outcome) was used, and additive 
coding was modeled as a set of dummy variables to avoid assumptions about linearity 
in the genotype—phenotype association.  Given that SNPs are known to affect disease 
risk in a variety of ways (i.e. dominant, recessive, heterozygote advantage, 
additive/multiplicative), the lack of replication may be explained by a difference in 
coding between CHARGE and Health ABC. Although the CHARGE GWAS stratified 
by smoke exposure (with never smokers analyzed separately from current and former 
smokers), there was no formal test of gene-environment interactions (for instance, 
with a product term between the SNP and smoking parameter).   
When the models from the 35 most statistically significant results in the Health 
ABC analyses were rerun using the coding and stratification strategies described in the 
CHARGE GWAS, only 2 of the 35 SNPs remained associated with the outcome at the 
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 level of statistical significance used to define the set of top hits (p<0.002). Clearly, 
decisions regarding coding of alleles and modeling of gene-environment interactions 
are of vital importance in genetic association studies.   
Another notable difference between the Health ABC study and the CHARGE 
GWAS meta-analysis is the demography of the populations studied.  The Health ABC 
population was about 40% Black, while all of the participants in the CHARGE 
analyses were of European ancestry (an important difference considering the 
proportionately higher number of findings among African Americans in the Health 
ABC results).  Also, the mean age of the participants in the CHARGE GWAS was 
considerably lower (58 vs 73 years) and, consistently, the mean FEV1 was higher 
(2,807 vs 2,215 ml); a smaller proportion of these populations may be experiencing 
the age-related increases in susceptibility to low lung function.  Population 
characteristics are also of vital importance in drawing comparisons between genetic 
epidemiology studies. 
 
Significance of This Work 
This dissertation was designed to address the susceptibility hypothesis, that is 
the hypothesis that COPD risk varies among cigarette smokers.  Understanding the 
determinants of susceptibility would enable identification of those at greatest risk of 
adverse outcomes and assist in targeting appropriate therapies to this population.  
Based on a number of observations in COPD epidemiology, this work investigates the 
hypothesis that variability in antioxidant defenses contribute to the variability in 
smoke exposure response observed in COPD risk.  Through explorations of both 
dietary and genetic sources of variation in antioxidant defenses, evidence has been 
provided in support of a role of antioxidant defenses in determining disease 
susceptibility.     
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 There are implications of this work beyond the scope of this particular research 
question, as well.  First, the dietary antioxidant—FEV1 decline paper provides key 
observations for the modeling of lung function decline.  While the tendency may be to 
include as many measurements of lung function as possible in order to have the most 
complete picture of lung function trajectory, careful consideration must be given to the 
timing of exposure measurements relative to the interval of decline for which those 
measurements are most appropriate.  For instance, there were statistically significant 
differences in the antioxidant—lung function decline association between participants 
whose oxidant burden changed during 4 years of follow-up and those without change 
(quitters vs. those who continued to smoke): having the most concurrent measures of 
oxidant burden was important in uncovering the antioxidant—lung function decline 
association in these participants.  Similarly, dietary antioxidant measured at the first 
year of follow-up appeared to be far more relevant to the earliest interval of decline 
(from baseline to the 4th year of follow-up) than to more distant intervals (including 
the 7th and 9th years of follow-up); an observation that is consistent with the changes in 
diet that are likely to occur during this life stage. 
Additional broad implications of this dissertation are provided by the 
antioxidant enzyme—lung function project.  In an era of research dominated by 
GWAS, there is still relevance in this hypothesis-oriented approach.  The biological 
hypotheses at the core of this work motivate design and analysis that incorporates 
factors of relevance to the biological model; the interaction between genes and 
smoking was central to the biological model, so every effort was made to effectively 
model this interaction within our analyses.  In contrast, the GWAS study on a similar 
question is not directly motivated by a biological model and gene-environment 
interactions were not considered, potentially masking the effects that would have been 
observed if the analysis were specifically looking at that question.     
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 Additionally, the discordance between the results by race deserve 
consideration.  In the SNPs project, there were proportionately more statistically 
significant results in African Americans, which may have been the end result of a 
greater burden of current smoking, a lower mean pulmonary function on average, or 
variability in genetic sequence. Disentangling this story is important, and has 
implications for other phenotypes as well.  These results suggest that not only are the 
conclusions from European Americans not directly transferable to other populations, 
but that variations in exposure to environmental and genetic factors may make study 
within African Americans a more informative design for discovery approaches for 
certain phenotypes.  Comparison of African Americans with Africans, who have 
similar genetic variation but different environmental exposures, may provide further 
insight into the extent to which these apparent racial differences may be the result of 
increased oxidative burden.  Similarly, a study conducted in European Americans with 
a greater proportion of current cigarette smokers may yield results more concordant 
with those currently observed in African Americans, providing support for the 
hypothesis that these differences are driven by proportion of participants under 
smoking-induced oxidative stress.  Continuing work on the African-American genome 
and disease associations from centers such as the National Human Genome Center 
(Howard University) and the Center for Research on Genomics and Global Health 
(National Human Genome Research Institute) will certainly offer further insight into 
this question. 
   
Future Directions 
 
While the work comprising this dissertation provides important evidence 
regarding the role of antioxidant defenses in COPD risk, it also suggests future 
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 directions for solidifying the understanding of this relation, particularly in regard to 
the most novel project conducted in this research, the association study between 
genetic variation in antioxidant enzymes and lung function.  Further work should be 
conducted within this population to consider haplotypes in the genes studied, and to 
consider different lung outcomes of importance in COPD risk, particularly rate of 
decline in FEV1, as lung function trajectory may isolate those who are particularly 
susceptible to adverse outcomes.  Also, other methods of investigating population 
substructure beyond self-reported race should be explored to further our understanding 
of the differences observed in these analyses.  Specifically, principal components 
analyses to identify meaningful subgroups of variability within participants and the 
use of admixture markers to represent degree of “African-ness” of African American 
participants would be useful methods of addressing the heterogeneity expected within 
groups defined imprecisely by race.  Additionally, the interrelatedness of the enzymes 
and nutrients suggest several further avenues for more direct investigation of gene-
nutrient interactions and gene-gene interactions.  Interaction between SNPs is 
biologically plausible given that many of these enzymes are linked in a pathway (i.e., 
with one enzyme providing a substrate/precursor for another, or enzymes sharing a 
common substrate).  Such an investigation would highlight not only genes, but 
pathways that are of particular relevance to reducing disease risk.  There is already 
evidence supporting interactions between some of these enzymes and dietary 
antioxidants: vitamin C can reduce glutathione from its oxidized disulfide 
conformation to the form with antioxidant activity (potentially affecting a whole range 
of glutathione-associated enzymes)(4); and, there is evidence for modification in 
expression and/or activity of selenoproteins with decreased selenium intake (5-9).  
Evidence of interactions between diet and SNPs in antioxidant enzymes would provide 
further understanding of etiology, but, importantly, would also suggest dietary 
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 antioxidants as a simple preventative intervention.   
Several of the genes highlighted in the antioxidant enzyme—lung function 
project have been considered minimally, if at all, as potential contributors to COPD 
susceptibility.  As such, further work at a basic science level is necessary to 
understand how these enzymes respond to oxidative insult.  Of particular importance 
is the preponderance of mitochondrial enzymes identified among the most statistically 
significant results.  Little work has been conducted to investigate the potential 
importance of the mitochondria in susceptibility to COPD, although there is some 
evidence of a role for the mitochondria in the excessive production of oxidative stress 
observed with cigarette smoke exposure.  This relation needs further investigation.  
As observational studies of dietary antioxidants and lung outcomes are for the 
most part positive across a broad range of exposure and outcome definitions, further 
work to investigate this relation should follow a different strategy to strengthen causal 
inference.  Specifically, one unanswered question is how increased antioxidant intake 
affects the lung tissue that is the site of the disease process.  Although the relation of 
antioxidant supplementation and systemic levels of antioxidants is well-established, 
there is little known about the effects of systemic supplementation on antioxidant 
levels in the relevant lung compartments: the epithelial lining fluid and associated 
cells, and in epithelial cells.  These dietary antioxidants may also exert an effect on 
expression of antioxidant enzymes, particularly those regulated with an antioxidant 
response element.  A pilot study of short-term antioxidant supplementation on 
smokers and subsequent changes in antioxidant concentration in the epithelial lining 
fluid and changes in gene expression is currently underway to investigate these 
questions. 
 
In summary, evidence generated in this dissertation supports the hypothesis 
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 that variability in antioxidant defenses contributes to the variability in risk of COPD 
observed among cigarette smokers.  While the specific mechanisms by which dietary 
antioxidants and antioxidant enzymes influence the lung function parameters 
associated with COPD risk remain to be elucidated, this work has contributed to the 
evidence base and has highlighted a number of questions for future research, 
particularly as related to the findings of the genetic association study. Based on the 
current evidence regarding the association between determinants of antioxidant 
defenses and lung outcomes, antioxidant strategies may offer a promising opportunity 
for the prevention of this prevalent and increasingly prominent disease.   
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 APPENDIX 
SUPPLEMENT A.1 
SEARCH STRATEGY AND RESULTS 
GENETIC VARIATION AND GENE EXPRESSION IN ANTIOXIDANT-
RELATED ENZYMES AND RISK OF CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE: A SYSTEMATIC REVIEW 
 
Searches of PubMed were conducted using the keywords “antioxidant” [AND] 
“gene” in combination with “COPD”, “emphysema”, and “chronic bronchitis.” 
Searches also considered disease keywords along with each of the enzymes of interest.  
Searches were performed up to August 2007.  Our interest was in enzymes and 
enzyme networks with direct antioxidant function, so the wide range of metal-related 
enzymes (e.g. heme oxygenase), which influence redox status indirectly by altering 
metal concentrations, were not considered.  Studies of systemic expression were not 
included as the relation between these values and expression levels in pulmonary cells 
and tissue is not well defined, making the contribution of these studies to the review 
questions unclear. Search results were supplemented by reviewing reference lists of 
identified papers. Only original research was considered. Searches identified 223 
articles for consideration.  Exclusions were made for the following reasons: not 
original research (57); not on adult humans (56); not genes of interest (9); outcome not 
disease or lung function (in association studies: 2); exposure not disease or smoking 
(in expression studies: 32); expression studies of cells or tissues that were not lung-
specific (23); not an association or expression study (7).  After reviewing reference 
lists, an additional 7 studies were added, for a total of 29 genetic association studies 
and 14 studies evaluating differential expression of antioxidant genes in lung tissue.  
All studies considered are summarised briefly in Table A.2. 
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TABLE A.2 
 
CHARACTERISTICS OF INCLUDED STUDIES 
GENETIC VARIATION AND GENE EXPRESSION IN ANTIOXIDANT-
RELATED ENZYMES AND RISK OF CHRONIC OBSTRUCTIVE  
PULMONARY DISEASE: A SYSTEMATIC REVIEW 
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Association Studies 
Ref First Author, 
 Pub Year 
Gene Populations Compared Outcome of Interest 
     
1  Hu, 2006 GCLM Chinese COPD patients and asymptomatic smokers COPD 
2  Liu, 2007 GCLC Chinese COPD patients and controls (matched gender, age, smoking) COPD 
3  Cheng, 2004 GSTM1 
GSTP1 
GSTT1 
Taiwanese COPD patients and asymptomatic smokers COPD 
4  Yanchina, 2007 GSTM1 Russian male COPD patients and asymptomatic smokers COPD 
5  Dialyna, 2003 GSTM1 Greek lung cancer patients with COPD and with pulmonary fibrosis or 
tuberculosis (both groups include smokers and nonsmokers) 
COPD 
6  Hersh, 2005 GSTM1 
GSTP1 
White American emphysema patients (smokers and nonsmokers) and 
asymptomatic ever smokers 
Emphysema 
7  Harrison, 1997 GSTM1 Scottish lung cancer patients with emphysema (smokers), with lung cancer 
only (smokers), and healthy blood donors (unknown smoking status) 
Emphysema 
8  Budhi, 2003 GSTM1 
GSTP1 
GSTT1 
Japanese male heavy smokers with and without emphysematous changes Emphysematous changes 
9  Baranov, 1996 GSTM1 French chronic bronchitis patients and asymptomatic individuals Chronic Bronchitis 
10  Baranova, 1997 GSTM1 French smokers: chronic bronchitis, asymptomatic  Chronic Bronchitis 
11  Imboden, 2007 GSTM1 
GSTP1 
GSTT1 
Predominantly European Caucasian general population (smokers and 
nonsmokers) 
Rate of decline: FEV1, 
FVC, FEF25-75 
12  Tkacova, 2004 GSTM1 
GSTT1 
Slovakian smokers with lung cancer  FEV1 % predicted, FVC 
% predicted 
13  Calikoglu, 2006 GSTM1 
GSTP1 
GSTT1 
Turkish male COPD patients and controls (matched on age and smoking 
status) 
COPD 
14  Ishii, 1999 GSTP1 Japanese COPD patients and asymptomatic smokers COPD 
15  Vibhuti, 2007 GSTP1 Indian COPD patients and asymptomatic smokers COPD, FEV1 % predicted 
16  He, 2004 GSTM1 
GSTP1 
GSTT1 
White North American smokers Highest vs. lowest 
quintile of FEV1 % 
predicted 
TABLE A.2 (continued) 
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Ref First Author, 
Pub Year 
Gene Populations Compared Outcome of Interest 
     
17  Hersh, 2006 GSTM1 
GSTP1 
mGST1 
White American emphysema patients  FEV1 % predicted 
18  He, 2002 GSTM1 
GSTP1 
GSTT1 
White North American smokers  Risk of steepest vs. 
slowest quintile of rate of 
FEV1 decline 
19  Mak, 2007 SOD2  
CAT 
Chinese COPD patients and asymptomatic ever smokers COPD 
20  Juul, 2006 SOD3 Danish COPD patients and asymptomatic individuals COPD, incidence of 
COPD hospitalization, 
FEV1 % predicted, FVC 
% predicted, FEV1/FVC 
21  Young, 2006 SOD1 
SOD2 
SOD3  
CAT 
COPD patients, asymptomatic smokers, and healthy blood donors (all of 
European descent) 
COPD 
22  Chan-Yeung, 
2007 
GSTM1 
GSTP1 
GSTT1 
Chinese COPD patients and controls (matched on age and smoking 
history) 
COPD 
23  Korytina, 2004 GSTM1 
GSTP1 
Russian COPD patients and asymptomatic individuals  COPD 
24 Lu, 2002 GSTP1 Chinese male COPD patients and asymptomatic smokers COPD 
25  Rodriguez, 2005 GSTP1 Spanish COPD patients and asymptomatic individuals COPD 
26  Yim, 2002 GSTP1 Korean COPD patients (smokers and nonsmokers) and asymptomatic 
smokers 
COPD 
27  Harries, 1997 GSTP1 Scottish Caucasian COPD patients and healthy individuals COPD 
28  Xiao, 2004 GSTP1 Chinese COPD patients and asymptomatic individuals COPD 
29  Yim, 2000 GSTM1 
GSTT1 
Korean COPD patients (smokers and nonsmokers) and asymptomatic 
smokers 
COPD 
TABLE A.2 (continued) 
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Expression Studies 
Ref First Author,  
Pub Year 
Gene Populations Compared Tissue Type(s) Assay Method(s) 
      
30  Rahman 2000 GCLC COPD patients and asymptomatic ever smokers 
(all undergoing lung resection for cancer) 
Alveolar epithelium, airway 
epithelial cells  
In situ hybridisation 
31  Lin 2005 GCLC COPD patients and patients without COPD (all 
undergoing lung resection for tumor) 
Alveoli, bronchi, inflammatory 
cells  
In situ hybridization, 
Immunohistochemistry 
32  Harju 2002 GCLC 
GCLM 
COPD patients (smokers), asymptomatic 
smokers, and asymptomatic nonsmokers (all 
undergoing lung resection for tumor) 
Bronchioli epithelium, central 
bronchus epithelium, alveolar 
macrophages   
Immunohistochemistry 
33  Neurohr 2003 GCLC 
GCLM 
Asymptomatic smokers and nonsmokers Alveolar macrophages RT-PCR 
34  Pierrou 2007 Many COPD patients at various stages, asymptomatic 
smokers, and nonsmokers 
Bronchial epithelial cells   Microarray 
35  Hackett 2003 Many Asymptomatic smokers and nonsmokers Airway epithelial cells  Microarray 
36  Tomaki 2007 Many COPD patients, smokers, and nonsmokers (all 
undergoing lung resection for cancer) 
Peripheral lung tissue RT-PCR 
37  Comhair 2000 GPX3 Asymptomatic smokers and nonsmokers Airway epithelial cells, alveolar 
macrophages 
Northern blot 
38  Peltoniemi 
2006 
GLRX COPD patients at various stages and smokers 
without COPD (all undergoing lung resection 
for tumor or lung transplantation for advanced 
COPD) 
Lung tissue homogenate, sputum 
supernatants 
Western blot 
39 Heguy 2006 G6PD Asymptomatic smokers and nonsmokers Alveolar macrophages Microarray 
40  Harju 2007 GSTO1 COPD patients at various stages, smokers 
without COPD, and nonsmokers (all undergoing 
lung resection for tumor or lung transplantation 
for advanced COPD) 
Alveolar epithelium, bronchial 
epithelium, lung tissue 
homogenate, sputum, alveolar 
macrophages, pulmonary blood 
vessels 
Immunohistochemistry, 
Western blot 
TABLE A.2 (continued) 
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Ref First Author,  
Pub Year 
Gene Populations Compared Tissue Type(s) Assay Method(s) 
      
41 Yigla 2007 SOD Smokers with COPD, nonsmokers with 
COPD, asymptomatic smokers, and 
asymptomatic nonsmokers 
Bronchoalveolar lavage fluid Enzyme assay 
42  Harju 2004 SOD1 
SOD2 
SOD3 
Smokers (with COPD GOLD stage 0-2) and 
nonsmokers;  
Smokers with COPD, asymptomatic smokers, 
and asymptomatic nonsmokers (all undergoing 
lung resection for tumor) 
Lung tissue homogenate, central 
bronchus epithelium, bronchioli 
epithelium, alveolar epithelium, 
alveolar macrophages, pulmonary 
blood vessels 
Western blot, 
immunohistochemistry 
43  Kondo 1994 SOD1 Asymptomatic elderly male smokers and 
nonsmokers  
Alveolar macrophages Northern blot 
 
*reference number linked to bibliography (Supplement A.5) 
  
 
TABLE A.3 
 
GENETIC ASSOCIATION STUDIES OF GENES RELATED TO  
ANTIOXIDANT FUNCTION IN PATIENTS WITH COPD IN COMPARISON  
TO CONTROLS  
 
GENETIC VARIATION AND GENE EXPRESSION IN ANTIOXIDANT-
RELATED ENZYMES AND RISK OF CHRONIC OBSTRUCTIVE  
PULMONARY DISEASE: A SYSTEMATIC REVIEW 
 
Most association studies reported odds ratios and 95% confidence intervals. 
When odds ratios were not given or used the variant genotype as the reference group, 
these measures were recalculated by the authors. Confounder-adjusted models were 
used when available. Quality of studies was evaluated in four categories of study 
features: population selection, exposure assessment, outcome assessment, and 
handling of covariates.  Each study was scored on whether the presented methods did 
(“+”) or did not (“-”) appropriately address potential bias in that category (“+”), or 
whether risk of bias could not be determined from given information (“0”). The 
detailed results across all studies are presented by gene in functional groups, and 
studies are repeated in the table if they included data on more than one gene or variant.  
Association studies are sorted within groups of genes by the outcome or group 
considered; for example, COPD and related diagnoses are considered before 
quantitative traits. 
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Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
Glutathione Synthesis 
GCLC C Æ T at -129  Results in decreased expression 44 rs17883901 
Liu 2007 Han Chinese 
C/C 
COPD patients (166) 41.6 
ref 
+0++ 
Healthy controls (166) 48.2 
C/T 
COPD patients (166) 58.4 
1.83 (1.00, 3.36) 
Healthy controls (166) 51.8 
GCLM C Æ T at -588 Results in decreased plasma glutathione 45 rs41303970 
Hu 2006 Chinese  
C allele 
COPD patients (104) 79.2  
ref  
+0+- 
 
Asymptomatic smokers (124) 91.9 
T allele 
COPD patients (104) 20.8 
3.0 (1.7, 5.3) 
Asymptomatic smokers (124) 8.1 
Glutathione Antioxidant Activity and Recycling 
(No studies) 
Glutathione Conjugation and Export 
GSTM1 NULL  Homozygous deletion resulting in complete lack of activity 46 
Calikoglu 
2006 Turkish men Null 
Stable COPD patients (149) 48.6 1.38 (0.87, 2.19) 
+0++ 
Healthy controls (150) 40.7 ref 
Chan-
Yeung 
2007
Chinese Null 
COPD patients (163) 60.1 1.16 (0.74, 1.80) 
+0++ 
Healthy controls (163) 56.5 ref 
Cheng 
2004 Taiwanese  Null 
COPD patients (184) 61.4 2.2 (1.3, 3.5) 
+0++ 
Asymptomatic controls (212) 42.5 ref 
Korytina 
2004 Russian  Null 
COPD patients (104) 50.5 1.37 (0.83, 2.25) 
-00- 
Asymptomatic controls (164) 42.7 ref 
TABLE A.3 (continued) 
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Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
Yanchina 
2004 Russian men Null 
COPD patients (72) 38.9 2.47 (1.10, 5.54) 
00-- 
Asymptomatic smokers (39) 20.5 ref 
Yim 2000 Korean  Null 
COPD patients (83) 57.0 0.72 (0.38, 1.36) 
-0+- 
Asymptomatic smokers (76) 65.0 ref 
Dialyna 
2003 
Greek lung cancer 
patients Null 
COPD patients (includes non-smokers)(21) 66.7 8.0 (1.32, 48.18) ix 
-0-- Patients with a history of pulmonary fibrosis or tuberculosis 
(includes non-smokers)(10) 20.0 ref 
Hersh 
2005 White American Null 
Emphysema patients (includes non-smokers) (304)  58.0 1.17 (0.87, 1.57) 
+0++ 
Asymptomatic males with smoking history (441) 54.0 ref 
Harrison 
1997 
Scottish lung 
cancer patients 
undergoing 
resection surgery 
Null 
Patients with Emphysema  (111) 65.0 
1.78 (0.93, 3.41)iv
1.61 (1.04, 2.50) v 
 -++0 
 Patients with lung cancer only (57) 51.0 ref 
Healthy blood donors (384)  53.0 ref 
Baranov 
1996 French  Null 
Severe Chronic Bronchitis (53) 73.6 3.47 (1.68, 7.16) 
-00- Mild Chronic Bronchitis (22) 40.9 0.86 (0.34, 2.20) 
No Chronic Bronchitis (101) 44.6 ref 
Baranova 
1997 French  Null 
Severe Chronic Bronchitis (87) 71.3 3.01 (1.74, 5.21) 
++++ Moderate Chronic Bronchitis (102) 65.7 2.15 (1.30, 3.57) 
No Chronic Bronchitis (172) 47.1 ref 
Budhi 
2003 Japanese Null 
Heavy smokers with emphysematous changes (63) 57.1 1.1 (0.6, 2.0) 
00++ 
Heavy smokers without emphysematous changes (172) 54.1 ref 
He 2002 
Predominantly 
White North 
American 
Null 
Smokers with steepest decline in FEV1 (299) 
47.4 0.95 (0.6, 1.35) 
++++ 
Smokers with slowest decline in FEV1 (322) 50.2 ref 
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Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
Null Linear regression of genotype on FEV1 ml decline/yr (4686) 52.9 
Men: -2.1(-4.5,0.3) viii 
Women: 0.5(-1.2,2.2) ++++ 
He 2004 White North American Null 
Smokers with lowest FEV1 % predicted (544) 54.0 1.09 (0.83, 1.42) ++++ 
Smokers with highest FEV1 % predicted (544)  54.3 ref  
Hersh 
2006 
White American 
emphysema 
patients 
Null Linear regression of genotype on FEV1 % predicted (304) NA p> 0.10 +0++ 
Tkacova 
2004 
Slovakian lung 
cancer patients Null 
GSTM1 Null: Mean FEV1 % predicted = 75.8 ± 2.5 (110) 49.0 
p<0.02 -+++ 
GSTM1 Non-null: Mean FEV1 % predicted = 86.6 ± 3.6 
(110) 51.0 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
Null Linear regression of genotype on FVC ml decline/yr (4686) 52.9 Men: -0.8(-4.0,2.5) 
viii 
Women: 1.1(-1.2,3.4) ++++ 
Tkacova 
2004 
Slovakian lung 
cancer patients Null 
GSTM1 Null: Mean FVC % predicted = 83.9 ± 2.1 (110) 49.0 
p<0.01 -+++ 
GSTM1 Non-null: Mean FVC % predicted = 90.3 ± 2.0 
(110) 51.0 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
Null Linear regression of genotype on FEF25-75 ml decline//yr (4686) 52.9 
Men: -4.1(-9.2,0.9) viii 
Women:-0.8(-4.7,3.1) ++++ 
GSTP1 Ile105Val  AÆG at nucleotide 313, changes affinity for specific substrates: valine substitution increased detoxification activity of the enzyme when 
challenged with polycyclic aromatic hydrocarbons and decreased activity is observed with other substrates (e.g. 1-chloro-2,4-dinitrobenzene). 47, 48 Val substitution 
has higher heat stability than Ile 49 rs1695 
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Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
Calikoglu 
2006 Turkish men 
A/A 
Stable COPD patients (149) 61.1 
ref 
+0++ 
Healthy controls (150) 38.0 
A/G 
Stable COPD patients (149) 29.2 
0.47 (0.28, 0.80) 
Healthy controls (150) 38.0 
G/G 
Stable COPD patients (149) 9.7 
0.25 (0.12, 0.50) 
Healthy controls (150) 24.0 
Chan-
Yeung 
2007 
Chinese 
A/A 
COPD patients (163) 68.7 
ref 
+0++ 
Healthy controls (163) 69.6 
A/G 
COPD patients (163) 26.4 
0.91 (0.56, 1.49) 
Healthy controls (163) 29.2  
G/G 
COPD patients (163) 4.9 
4.0 (0.83, 19.25)ix 
Healthy controls (163) 1.2 
Cheng 
2004 Taiwanese  
A/A 
COPD patients (184) 52.7  
ref 
 
+0++ 
 
 
Asymptomatic controls (212) 46.7 
A/G 
COPD patients (184) 42.4 
0.81 (0.54, 1.22) 
Asymptomatic controls (212) 46.2 
G/G 
COPD patients (184) 4.9 
0.61 (0.26, 1.47) 
Asymptomatic controls (212) 7.1 
Harries 
1997 
Caucasians 
(Scottish) 
A/A 
COPD patients (79) 43.0 
ref 
-0-- 
Healthy individuals (155) 51.0 
A/G 
COPD patients (79) 44.3 
1.23 (0.69, 2.19) 
Healthy individuals (155) 42.5 
G/G COPD patients (79) 12.7 2.32 (0.89, 6.09) 
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Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
Healthy individuals (155) 6.5 
Ishii 1999 Japanese  
A/A 
COPD patients (53) 79.0 
ref 
+0+- 
Asymptomatic smokers (50) 52.0 
A/G 
COPD patients (53) 21.0 
0.31 (0.13, 0.74) 
Asymptomatic smokers (50) 44.0 
G/G 
COPD patients (53) 0.0 
NA 
Asymptomatic smokers (50) 4.0 
Korytina 
2004 Russian 
A/A 
COPD patients (104) 59.1 
ref 
-00- 
Asymptomatic controls (164) 63.2 
A/G 
COPD patients (104) 33.7 
1.07 (0.62, 1.83) 
Asymptomatic controls (164) 33.5 
G/G 
COPD patients (104) 7.2 
2.29 (0.69, 7.53) 
Asymptomatic controls (164) 3.3 
Lu 2002 Chinese men 
A/A 
COPD patients (97) 72.0 
ref 
+0++ 
Asymptomatic smokers (67) 61.0 
A/G 
COPD patients (97) 23.0 
0.54 (0.27, 1.08) 
Asymptomatic smokers (67) 36.0 
G/G 
COPD patients (97) 5.0 
1.46 (0.27, 7.89) ix 
Asymptomatic smokers (67) 3.0 
 
 
 
Rodriguez 
2005 
 
Spanish  
A/A 
COPD patients (99) 53.1 
49 0 ref 
-+++ 
Asymptomatic smokers and nonsmokers (198) 49.0 
A/G 
COPD patients (99) 36.7 
0.76 (0.46, 1.28) 
Asymptomatic smokers and nonsmokers (198) 44.0 
G/G COPD patients (99) 10.2 1.43 (0.59, 3.50) 
TABLE A.3 (continued) 
 
 
 
104
Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
 Asymptomatic smokers and nonsmokers (198) 6.6 
Vibhuti 
2007 Indian smokers 
A/A 
COPD patients (202) 52.0 
ref 
00++ 
Healthy individuals (136) 66.2 
A/G 
COPD patients (202) 37.1 
1.53 (0.96, 2.45) 
Healthy individuals (136) 30.9 
G/G 
COPD patients (202) 10.9 
4.71 (1.57, 14.2) ix 
Healthy individuals (136) 2.9 
Xiao 2004 Chinese 
A/A 
COPD patients (includes nonsmokers)(100) 57.0 
ref 
-0++ 
Asymptomatic smokers and nonsmokers (100) 70.0 
A/G 
COPD patients (includes nonsmokers) (100) 40.0 
1.69 (0.94, 3.06) 
Asymptomatic smokers and nonsmokers (100) 29.0 
G/G 
COPD patients (includes nonsmokers) (100) 3.0 
3.68 (0.37, 36.38) ix 
Asymptomatic smokers and nonsmokers (100) 1.0 
Yim 2002 Korean  
A/A 
COPD patients (includes never-smokers) (89) 71.0 
ref 
-0+- 
Asymptomatic smokers (94) 61.0 
A/G 
COPD patients (includes never-smokers) (89) 27.0 
0.62 (0.33, 1.17) 
Asymptomatic smokers (94) 37.0 
G/G 
COPD patients (includes never-smokers) (89) 2.0 
0.90 (0.12, 6.64) ix 
Asymptomatic smokers (94) 2.0 2.0 
Hersh 
2005vi White American 
A allele 
Emphysema patients (includes nonsmokers) (304) 
 65.0 ref 
+0++ 
Asymptomatic males with smoking history (441) 70.0 
G allele Emphysema patients (includes nonsmokers) (304) 35.0 1.25 (0.92, 1.71) 
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Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
Asymptomatic males with smoking history (441) 30.0 
Budhi 
2003 Japanese 
A/A 
Heavy smokers with emphysematous changes (63) 77.8 
ref 
00++ 
Heavy smokers without emphysematous changes (172) 73.3 
A/G 
Heavy smokers with emphysematous changes (63) 20.6 
0.78 (0.39, 1.57) 
Heavy smokers without emphysematous changes (172) 25.0 
G/G 
Heavy smokers with emphysematous changes (63) 1.6 
0.86 (0.09, 8.44) ix 
Heavy smokers without emphysematous changes (172) 1.7 
He 2002 
Predominantly 
White North 
American 
A/A 
Smokers with steepest decline in FEV1 (299) 40.0 ref 
++++ 
Smokers with slowest decline in FEV1 (322) 39.0 
A/G 
Smokers with steepest decline in FEV1 (299) 48.6 0.92 (0.66, 1.31) 
Smokers with slowest decline in FEV1 (322) 51.2 
G/G 
Smokers with steepest decline in FEV1 (299) 11.4 1.12 (0.64, 1.97) 
Smokers with slowest decline in FEV1 (322) 9.8 
He 2004 White North American 
A/A 
Smokers with lowest FEV1 % predicted (544) 44.7 ref 
++++ 
Smokers with highest FEV1 % predicted (544) 44.7 
A/G 
Smokers with lowest FEV1 % predicted (544) 42.1 0.65 (0.43, 0.97) 
Smokers with highest FEV1 % predicted (544) 46.0 
G/G 
Smokers with lowest FEV1 % predicted (544) 13.2 2.01 (1.14, 3.59) 
Smokers with highest FEV1 % predicted (544) 9.3 
Vibhuti 
2007 Indian smokers 
A/A COPD patients: FEV1 % predicted 61.9 ± 29.6 L (105) 52.0 
p > 0.05 00++ A/G & 
G/G COPD patients: FEV1 % predicted 57.7 ± 24.1 L (97) 48.0 
Vibhuti 
2007 Indian smokers A/A 
Asymptomatic smokers: FEV1 % predicted 110.7 ± 22.4 L 
(90) 66.2 p > 0.05 00++ 
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Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
A/G & 
G/G 
Asymptomatic smokers: FEV1 % predicted 109.1 ± 16.7 L 
(46) 33.8 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
A/G Linear regression of genotype on FEV1 ml decline/yr (4686) 43.2 
Men:0.09(-2.4,2.6) viii 
Women:-0.6(-2.4,1.2) ++++ 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
G/G Linear regression of genotype on FEV1 ml decline/yr (4686) 9.4 
Men: -2.5(-6.6,1.7) viii 
Women:-0.2(-3.3,2.9) ++++ 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
A/G Linear regression of genotype on FVC ml decline/yr (4686) 43.2 Men: -0.1(-3.5,3.3) 
viii 
Women: 0.6(-1.8,3.0) ++++ 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
G/G Linear regression of genotype on FVC ml decline/yr (4686) 9.4 Men: -3.2(-9.0,2.5)
 viii 
Women: 1.5(-2.6,5.6) ++++ 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
A/G Linear regression of genotype on FEF25-75 ml decline/yr (4686) 43.2 
Men: -2.7(-8.0,2.6) viii 
Women:-3.0(-7.0,1.1) ++++ 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
G/G Linear regression of genotype on FEF25-75 ml decline/yr (4686) 9.4 
Men:-7.3(-16.1, 1.6)viii 
Women: 0.5(-6.5,7.5) ++++ 
Hersh 
2006 
White American 
emphysema 
patients 
 Linear regression of an additive genetic model on FEV1 % predicted (304) NA p> 0.10 +0++ 
GSTP1 Ala114Val  C→T at nucleotide 341, changes Ala to Val at 114 50 rs1138272 
Ishii 1999 Japanese  C/C 
COPD patients (53)  100 Could not be 
calculated +0+- Asymptomatic smokers (50) 100 
Vibhuti 
2007 Indian smokers 
C/C 
COPD patients (202) 60.9 
Ref 
00++ Healthy individuals (136) 77.9 
C/T COPD patients (202) 28.2 1.56 (1.08, 2.70) 
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Reference Population descriptioni Genotype Subgroups (n)
ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
Healthy individuals (136) 17.6 
T/T 
COPD patients (202) 10.9 
2.47 (1.15, 6.12) 
Healthy individuals (136) 4.4 
Hersh 
2005vi White American  
C allele 
Emphysema patients (includes nonsmokers) (304)  92.0 
Ref 
+0++ 
Asymptomatic males with smoking history (441) 91.0 
T allele 
Emphysema patients (includes nonsmokers) (304) 8.0  0.86 (0.51, 1.46) 
Asymptomatic males with smoking history (441) 9.0 
Hersh 
2006 
White American 
emphysema 
patients 
 Linear regression of additive genetic model on FEV1 % predicted in emphysema patients (304) NA p> 0.10 +0++ 
Vibhuti 
2007 Indian smokers 
C/C COPD patients: FEV1 % predicted 63.9 ± 28.5 L (123) 60.9 
p < 0.05 00++ C/T & 
T/T COPD patients: FEV1 % predicted 56.2 ± 22.4 L (79) 39.1 
Vibhuti 
2007 Indian smokers 
C/C Asymptomatic smokers: FEV1 % predicted 110.1 ± 21.2 L (106) 77.9 
p > 0.05 00++ 
C/T & 
T/T 
Asymptomatic smokers: FEV1 % predicted 109.4 ± 16.5 L 
(30) 22.1 
GSTT1 NULL  Homozygous deletion resulting in complete lack of activity 
Calikoglu 
2006 Turkish men Null 
Stable COPD patients (149) 14.6 1.22 (0.65, 2.29) 
+0++ 
Healthy controls (150) 17.3 ref 
Chan-
Yeung 
2007
Chinese Null 
COPD patients (163) 54.6 0.83 (0.54, 1.29) 
+0++ 
Healthy controls (163) 59.0 ref 
Cheng Taiwanese  Null COPD patients (184) 53.8 0.9 (0.6, 1.6) +0++ 
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ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
2004 Asymptomatic ever smokers (212) 52.8 ref 
Yim 2000 Korean  Null 
COPD patients (includes never-smokers) (83) 55.0 0.77 (0.41, 1.45) 
-0+- 
Asymptomatic smokers (76) 62.0 ref 
Budhi 
2003 Japanese Null 
Heavy smokers with emphysematous changes (63) 42.9 1.06 (0.6, 1.9) 
00++ 
Heavy smokers without emphysematous changes (172) 41.3 ref 
He 2002 
Predominantly 
White North 
American  
Null 
Smokers with steepest decline in FEV1 (299) 30.4 1.23 (0.83, 1.82) 
++++ 
Smokers with slowest decline in FEV1 (322) 25.1 ref 
He 2004 White North American Null 
Smokers with lowest FEV1 % predicted (544) 22.3 1.3 (0.94, 1.82) 
++++ 
Smokers with highest FEV1 % predicted (544) 17.8 ref 
Tkacova 
2004 
Slovakian lung 
cancer patients Null 
GSTT1 Null: Mean FEV1 % predicted = 81.4 ± 4.9 (110) 21.8 
p>0.05 -+++ 
GSTT1 Non-null: Mean FEV1 % predicted = 79.3 ± 2.3 
(110) 78.2 
Tkacova 
2004 
Slovakian lung 
cancer patients Null 
GSTT1 Null: Mean FVC % predicted = 89.3 ± 3.3 (110) 21.8 
p>0.05 -+++ GSTT1 Non-null: Mean FVC % predicted = 85.6 ± 1.7 
(110) 78.2 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
Null Linear regression of genotype on FEV1 ml decline/yr (4686) 18.0 
Men:-5.3(-8.4,-2.1)viii 
Women:-0.3(-2.5,1.8) ++++ 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
Null Linear regression of genotype on FVC ml decline/yr (4686) 18.0 Men:-5.2(-7.4,-1.3)
viii 
Women:-1.6(-4.5,1.3) ++++ 
Imboden 
2007 
European 
Caucasians 
(predominantly) 
Null Linear regression of genotype on FEF25-75 ml decline/yr (4686) 18.0 
Men:-5.0(-11.7, 1.8)viii 
Women:3.4 (-1.5,8.3) ++++ 
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Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
mGST1  G→A in the 3’ UTR.  rs11875 
Hersh 
2006 
White American 
emphysema 
patients 
 Linear regression: additive genetic model and FEV1 % predicted (304) NA p> 0.10 +0++ 
mGST1  G→A in the 3’ UTR.  rs2160512 
Hersh 
2006 
White American 
emphysema 
patients 
 Linear regression: additive genetic model and FEV1 % predicted (304) NA p> 0.10 +0++ 
mGST1  A→G in intron 1.  rs2239675 
Hersh 
2006 
White American 
emphysema 
patients 
 Linear regression: additive genetic model and FEV1 % predicted (304) NA p> 0.10 +0++ 
mGST1  A→T in intron 3.  rs2287152 
Hersh 
2006 
White American 
emphysema 
patients 
 Linear regression: additive genetic model and FEV1 % predicted (304) NA p> 0.10 +0++ 
Thioredoxin Metabolism 
(No studies) 
Other Antioxidant Enzymes 
SOD1  A→C substitution in intron 3 (+35), adjacent to a splice site 51 rs2234694 
Young 
2006 European descent  
A/A 
COPD patients (230) 92.0 
Ref 
++++ 
Asymptomatic smokers (210) 90.0 
A/C 
COPD patients (230) 7.0 
0.75 (0.38, 1.50) 
Asymptomatic smokers (210) 9.0 
C/C COPD patients (230) 1.0 0.89 (0.12, 6.39) ix 
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ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
Asymptomatic smokers (210) 1.0 
SOD2 Val16Ala T→C at nucleotide 47, changes Val to Ala at 16, possibly less efficient localisation to mitochondria 52 rs4880 
Young 
2006 European descent 
T/T 
COPD patients (230) 23.0 
Ref 
++++ 
Asymptomatic smokers (210) 22.0 
T/C 
COPD patients (230) 52.0 
0.92 (0.58, 1.48) 
Asymptomatic smokers (210) 54.0 
C/C 
COPD patients (230) 25.0 
0.97 (0.56, 1.68) 
Asymptomatic smokers (210) 24.0 
Mak 2007 Chinese 
T/T 
COPD patients (165) 72.6 
Ref 
++++ 
Asymptomatic ever smokers (165) 79.9 
T/C & 
C/C 
COPD patients (165) 27.4 
1.50 (0.90, 2.51) 
Asymptomatic ever smokers (165) 20.1 
SOD3 Arg213Gly C→G substitution at nucleotide 760, changes Arg to Gly at 213, resulting in decreased heparin affinity and increased plasma SOD3 content 53 
rs1799895 
Juul 2006 Danish  
C/C 
COPD patients (978) 99.0 
Ref 
++++ 
Asymptomatic smokers and nonsmokers (7604)  97.4 
C/G 
COPD patients (978) 1.5 
0.58 (0.34, 0.99) 
Asymptomatic smokers and nonsmokers (7604)  2.6 
G/G 
COPD patients (978) 0.0 
NA 
Asymptomatic smokers and nonsmokers (7604)  3.0 
Young 
2006 European descent  C/C 
COPD patients (230) 98.0 
ref ++++ Asymptomatic smokers (210) 91.0 
Healthy blood donors (190) 96.0 
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ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
C/G 
COPD patients (230) 2.0 
0.25 (0.09, 0.69) vii 
0.67 (0.20, 2.24) v Asymptomatic smokers (210) 8.0 
Healthy blood donors (190) 3.0 
G/G 
COPD patients (230) 0.0 
NA Asymptomatic smokers (210) 1.0 
Healthy blood donors (190) 1.0 
Juul 2006 Danish  
C/C Incidence of COPD hospitalization or death: 17%  ref 
++++ C/G Incidence of COPD hospitalization or death: 7%   0.3 (0.1, 0.8) 
G/G Incidence of COPD hospitalization or death: 0%  NA 
Juul 2006 Danish 
C/C Mean FEV1 % predicted: 85.0 ± 18% (8879) 97.6 p= 0.41 ++++ 
C/G Mean FEV1 % predicted: 85.5 ± 18% (8879) 2.4 
Juul 2006 Danish 
C/C Mean FEV1 % predicted (Smokers): 84.0 ± 19% (6906) 97.5 p=0.17 ++++ 
C/G Mean FEV1 % predicted (Smokers): 86.7 ± 20% (6906) 2.5 
Juul 2006 Danish 
C/C Mean FVC % predicted:  87.3 ± 16% (8879) 97.6 
p=0.32 ++++ 
C/G Mean FVC % predicted: 90.5 ± 16% (8879) 2.4 
Juul 2006 Danish 
C/C Mean FVC % predicted (Smokers): 88.5 ± 16% (6906) 97.5 
p=0.84 ++++ 
C/G Mean FVC % predicted (Smokers): 89.4 ± 16% (6906) 2.5 
Juul 2006 Danish 
C/C Mean FEV1 /FVC: 77.1 ± 9 (8879) 97.6 p=0.11 ++++ 
C/G Mean FEV1 /FVC: 78.2 ± 9 (8879) 2.4 
Juul 2006 Danish 
C/C Mean FEV1 /FVC (Smokers): 75.7 ± 11 (6906) 97.5 p=0.04 ++++ 
C/G Mean FEV1 /FVC (Smokers): 77.8 ± 9 (6906) 2.5 
CAT A→T in the promoter region (position -21), associated with acatalesemia 54 rs7943316 
Young European descent A/A COPD patients (230) 52.0 ref ++++ 
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ii 
Genotype 
Frequency 
(%) 
Odds Ratio (95% CI)  
Quality 
Score 
(PEOC)iii 
2006 Asymptomatic smokers (210) 48.0 
A/T 
COPD patients (230) 41.0 
0.90 (0.61, 1.33) 
Asymptomatic smokers (210) 42.0 
T/T 
COPD patients (230) 7.0 
0.64 (0.32, 1.29) 
Asymptomatic smokers (210) 10.0 
CAT C→T in the promoter region (position -262), associated with increased expression in red blood cells 55 rs1001179 
Mak 2007 Chinese 
C/C 
COPD patients (all ever smokers) (165) 90.9 
ref 
++++ 
Asymptomatic ever smokers (165) 93.3 
C/T & 
T/T 
COPD patients (all ever smokers) (165) 9.1 
1.40 (0.63, 3.14) 
Asymptomatic ever smokers (165) 6.7 
i Unless mentioned, all study populations included both men and women.   
ii Reference group is the last subgroup listed. 
iii Scores (+,0,-) are given for each of the following categories in this order: Population Selection, Exposure, Outcome Determination, and Covariate Handling. 
iv Reference group is participants with lung cancer only 
v Reference group is healthy blood donors 
vi Allele frequencies given instead of genotype frequencies 
vii Reference group is asymptomatic smokers 
viii Beta coefficient (95% CI) given for regression models 
ix Estimate based on group(s) with fewer than 5 participants
 
 
 
 
TABLE A.4 
 
GENE EXPRESSION STUDIES OF GENES RELATED TO ANTIOXIDANT 
FUNCTION IN PATIENTS WITH COPD IN COMPARISON TO CONTROLS, 
AND IN SMOKERS COMPARED TO NONSMOKERS. 
 
GENETIC VARIATION AND GENE EXPRESSION IN ANTIOXIDANT-
RELATED ENZYMES AND RISK OF CHRONIC OBSTRUCTIVE  
PULMONARY DISEASE: A SYSTEMATIC REVIEW 
 
Expression studies used a variety of assay types, limiting direct comparability 
across studies. To facilitate comparisons, the ratio of expression in one group to 
expression in the reference group was given. If not provided in the publication, ratios 
were calculated (using numeric estimates derived from graphs, where necessary). 
Quality of studies was evaluated in four categories of study features: population 
selection, exposure assessment, outcome assessment, and handling of covariates.  
Each study was scored on whether the presented methods did (“+”) or did not (“-”) 
appropriately address potential bias in that category (“+”), or whether risk of bias 
could not be determined from given information (“0”). Results of the expression 
studies are also sorted within groups of genes and then by tissue type, as follows: from 
small airways (alveolar epithelium), to large airways (central bronchus epithelium), to 
non-epithelial tissues. 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
Glutathione Synthesis 
GGT        
(No studies)       
GCLC        
Rahman 
2000 
Alveolar epithelium v  In situ 
hybridisation 
COPD patients (11) 
Asymptomatic ever smokers (12) 
1.81 ± 0.09 
GR 
1.42 ± 0.14  
1.27 
ref 
p<0.04 -++- 
Lin 2005 Alveoli v In situ 
hybridisation 
COPD patients (12) 
Patients without COPD (10)  
0.25 ± 0.05 
GR 
0.14 ± 0.03 
1.79 
ref 
p<0.05 -+0- 
Lin 2005 Alveoli v Immunohistoc
hemistry 
COPD patients (12) 
Patients without COPD (10)  
0.20 ± 0.04 
GR 
0.12 ± 0.04 
1.67 
ref 
p<0.05 -+0- 
Harju 
2002 
Bronchioli epithelium 
v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
1.5 ± 0.2 GR 
1.4 ± 0.1 
1.4 ± 0.2 
1.07 
1.00 
ref 
NS 
NS 
-++- 
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 2.29 
ref 
p=0.0004 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
1100 vi 
1199 
926 
960 
728 
1.51 
1.65 
1.27 
1.32 
ref 
 -++- 
Rahman 
2000 
Airway epithelial 
cells v 
In situ 
hybridisation 
COPD patients (11) 
Asymptomatic ever smokers (12) 
1.82 ± 0.17
GR 
1.42 ± 0.12 
1.28 
ref 
p=0.075 -++- 
Lin 2005 Bronchi v In situ 
hybridisation 
COPD patients (12) 
Patients without COPD (10)  
0.31 ± 0.05 
GR 
0.17 ± 0.04 
1.82 
ref 
p<0.05 -+0- 
Lin 2005 Bronchi v Immunohistoc
hemistry 
COPD patients (12) 
Patients without COPD (10)  
0.18 ± 0.02 
GR 
0.10 ± 0.03 
1.80 
ref 
p<0.05 -+0- 
Harju 
2002 
Central bronchus 
epithelium v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
1.6 ± 0.2 GR 
1.8 ± 0.2 
0.76 
0.86 
p=0.015  
NS 
-++- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
Asymptomatic nonsmokers (13) 2.1 ± 0.2 ref 
Neurohr 
2003 
Alveolar 
macrophages 
(bronchoalveolar 
lavage) 
RT-PCR Asymptomatic smokers (8) 
Asymptomatic nonsmokers (8) 
0.6 ± 0.1 RCE 
0.9 ± 0.2 
0.67 
ref 
NS 00+- 
Harju 
2002 
Alveolar 
macrophages v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
0.8 ± 0.1 GR 
0.4 ± 0.1 
1.5 ± 0.2 
0.52 
0.28 
ref 
p=0.053 
p<0.001 
-++- 
Lin 2005 Inflammatory cells v In situ 
hybridisation 
COPD patients (12) 
Patients without COPD (10)  
0.28 ± 0.06 
GR 
0.20 ± 0.05 
1.40 
ref 
p<0.05 -+0- 
Lin 2005 Inflammatory cells v Immunohistoc
hemistry 
COPD patients (12) 
Patients without COPD (10)  
0.25 ± 0.06 
GR 
0.14 ± 0.04 
1.79 
ref 
p<0.05 -+0- 
GCLM        
Harju 
2002 
Bronchioli epithelium 
v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
0.8 ± 0.05 
GR 
0.9 ± 0.1 
1.1 ± 0.1 
0.73 
0.82 
ref 
NS 
NS 
-++- 
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 2.5 
1.0 
p=0.04 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
788 
974 
712 
628 
429 
86 vi 
90 
86 
83 
66 
1.84 
2.27 
1.66 
1.46 
ref 
1.30 
1.36 
1.30 
1.26 
ref 
 -++- 
Harju 
2002 
Central bronchus 
epithelium v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
1.0 ± 0.1 GR 
1.0 ± 0.1 
1.6 ± 0.2 
0.63 
0.63 
ref 
p=0.006 
p=0.021 
-++- 
Harju 
2002 
Alveolar 
macrophages v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
1.1 ± 0.2 GR 
0.6 ± 0.1 
1.6 ± 0.2 
0.69 
0.38 
ref 
NS 
p<0.001 
-++- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
Neurohr 
2003 
Alveolar 
macrophages 
(bronchoalveolar 
lavage) 
RT-PCR Asymptomatic smokers (8) 
Asymptomatic nonsmokers (8) 
0.6 ± 0.1 RCE 
2.8 ± 0.4 
0.21 
ref 
p<0.01 00+- 
GSS        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.27 
ref 
p=0.08 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
369 vi      
398 
388 
355 
373 
0.99 
1.07 
1.04 
0.95 
ref 
 -++- 
Glutathione Antioxidant Activity and Recycling 
GPX        
GPX1        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.15 
ref 
p=0.61 ++++ 
GPX2        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 5.09 
ref 
p<0.00001 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
1551 vi     
1784 
1715 
1437 
427 
3.63 
4.18 
4.02 
3.37 
ref 
 -++- 
GPX3        
Comhair 
2000 
Airway epithelial 
cells (bronchoscopy) 
Northern blot Asymptomatic smokers (11) 
Asymptomatic nonsmokers (12) 
18  ± 3  RCE 
8.0 ± 0.8 
2.25 
ref 
p<0.05 +0+0 
Hackett Airway epithelial Microarray Asymptomatic smokers (13)  1.86 p=0.007 ++++ 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
2003  cells (bronchoscopy) Asymptomatic nonsmokers (9) ref 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
568 vi       
665 
536 
526 
454 
1.25 
1.46 
1.18 
1.16 
ref 
 -++- 
Tomaki 
2007 
Peripheral lung tissue 
(lung resection) v 
 
RT-PCR COPD patients (smokers) (14) 
Smokers (9) 
Nonsmokers (10) 
0.831 ± 0.206 
1.030 ± 0.117 
0.736 ± 0.178 
1.13 
1.40 
ref 
NS 
NS 
-++- 
Comhair 
2000 
Alveolar 
Macrophages 
(bronchoalveolar 
lavage) 
Northern blot Asymptomatic smokers (11) 
Asymptomatic nonsmokers (12) 
44 ± 10 RCE 
24 ± 3 
1.83 
ref 
p<0.05 +0+0 
GPX4        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.10 
ref 
p=0.61 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
1571 vi     
2102 
1463 
1526 
1650 
0.95 
1.27 
0.89 
0.92 
ref 
 -++- 
GPX5        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
108 vi      
99 
110 
117 
97 
1.11 
1.02 
1.13 
1.21 
ref 
 -++- 
GPX7        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
82 vi        
84 
0.94 
0.97 
 -++- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
85 
84 
87 
0.98 
0.96 
ref 
GLRX        
GLRX        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
364 vi 
291 
337 
302 
306 
1.19 
0.95 
1.10 
0.99 
ref 
 -++- 
Peltoniem
i 2006 
Lung tissue 
homogenate v 
(resection/transplantat
ion) 
Western Blot 
Analysis 
COPD patients, stage I-II (9) 
COPD patients, stage IV (6) 
Asymptomatic smokers (9) 
Nonsmokers (8) 
 0.86 
0.81 
1.09 
ref 
NS/p=0.04
5vii 
NS/p=0.02
2 vii 
NS 
 
-0+- 
Peltoniem
i 2006 
Sputum supernatants  Western Blot 
Analysis 
COPD patients (exacerbation) (7) 
Stable COPD, stage 0-I (17) 
Asymptomatic smokers (11) 
Nonsmokers (15) 
 1.33 
1.16 
1.07 
P=0.013 
NS 
NS 
-0+- 
GSR        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 2.31 
ref 
p=0.03 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
340 vi       
372 
368 
304 
210 
1.62 
1.77 
1.75 
1.45 
ref 
 -++- 
G6PD        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.85 
ref 
p<0.00001 ++++ 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
291 vi       
345 
286 
269 
155 
1.88 
2.23 
1.85 
1.74 
ref 
 -++- 
Heguy 
2006 
Alveolar 
Macrophages 
(bronchoscopy) 
Microarray Asymptomatic smokers (5) 
Asymptomatic nonsmokers (5) 
 2.1 
1.0 
p<0.011 ++++ 
Glutathione Conjugation and Transport 
GST        
GSTA1        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
4881 vi     
5070 
3881 
4722 
4274 
1.14 
1.19 
0.91 
1.10 
ref 
 -++- 
Tomaki 
2007 
Peripheral lung tissue 
(lung resection) v 
 
RT-PCR COPD patients (smokers) (14) 
Smokers (9) 
Nonsmokers (10) 
0.126 ± 0.019 
0.229 ± 0.044 
0.136 ± 0.033 
0.93 
1.68 
ref 
NS 
p<0.05 
-++- 
GSTA2        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.48 
ref 
p=0.0025 ++++ 
GSTM3        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.44 
ref 
p=0.38 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
135 vi      
205 
174 
127 
86 
1.57 
2.38 
2.02 
1.48 
ref 
 -++- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
GSTM4 
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.5f4 
ref 
p=0.21 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
440 
460 
523 
454 
549 
199 vi 
209 
222 
208 
221 
0.80 
0.84 
0.95 
0.83 
ref 
0.90 
0.95 
1.00 
0.94 
ref 
 -++- 
GSTO1        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
789 vi       
791 
647 
653 
614 
1.29 
1.29 
1.05 
1.06 
ref 
 -++- 
Harju 
2007 
Alveolar epithelium 
(resection v or lung 
transplantation)  
 
Immunohistoc
hemistry 
COPD, stage I-II (CS) (26) 
COPD, stage IV (ex-smokers) (8) 
Asymptomatic CS (22) 
Lifelong non-smokers (16) 
0.6 ± 0.1GR 
1.0 ± 0.1 
0.5 ± 0.1 
0.5 ± 0.1 
1.2 
2.0 
1.0 
ref 
NS 
p<0.05 
NS 
-+00 
Harju 
2007 
Bronchial epithelium 
(resection v or lung 
transplantation)  
 
Immunohistoc
hemistry 
COPD, stage I-II (CS) (26) 
COPD, stage IV (ex-smokers) (8) 
Asymptomatic CS (22) 
Lifelong non-smokers (16) 
0.2 ± 0.1GR 
0.6 ± 0.1 
0.3 ± 0.1 
0.3 ± 0.1 
0.7 
2.0 
1.0 
ref 
NS 
NS 
NS 
-+00 
Harju 
2007 
Lung tissue 
homogenate 
(resection) v 
 
Western Blot 
Analysis 
COPD patients (CS) (17) 
Asymptomatic CS (5) 
Lifelong non-smokers (9) 
 0.80 
1.01 
ref 
p=0.003 
NS 
-+00 
Harju 
2007 
Induced sputum v Western Blot 
Analysis 
COPD patients (CS) (15) 
Asymptomatic CS (5) 
Lifelong non-smokers (6) 
 0.67 
0.97 
ref 
p=0.023 
NS 
-+00 
Harju 
2007 
Alveolar 
macrophages 
(resection v or lung 
transplantation)  
Immunohistoc
hemistry 
COPD, stage I-II (CS) (26) 
COPD, stage IV (ex-smokers) (8) 
Asymptomatic CS (22) 
Lifelong non-smokers (16) 
1.8 ± 0.1GR 
1.7 ± 0.1 
1.4 ± 0.1 
1.5 ± 0.1 
1.2 
1.1 
0.9 
ref 
NS 
NS 
NS 
-+00 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
 
Harju 
2007 
Pulmonary blood 
vessels (resection v or 
lung transplantation)  
 
Immunohistoc
hemistry 
COPD, stage I-II (CS) (26) 
COPD, stage IV (ex-smokers) (8) 
Asymptomatic CS (22) 
Lifelong non-smokers (16) 
0.15 ± 0.2GR 
0.5 ± 0.2 
0.15 ± 0.0 
0.3 ± 0.1 
0.5 
1.7 
0.5 
ref 
NS 
NS 
NS 
-+00 
GSTP1 
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 0.97 
ref 
p=0.98 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
2983 vi     
3448 
2711 
2895 
2837 
1.05 
1.22 
0.96 
1.02 
ref 
 -++- 
GSTT1 
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.60 
ref 
p=0.25 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
214 vi       
237 
210 
221 
233 
0.92 
1.02 
0.90 
0.95 
ref 
 -++- 
GSTT2 
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.06 
ref 
p=0.89 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
77 vi       
63 
67 
72 
71 
1.08 
0.89 
0.94 
1.01 
ref 
 -++- 
GSTZ1 
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.01 
ref 
p=0.92 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
179 vi       
187 
1.04 
1.09 
 -++- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
186 
179 
172 
1.08 
1.04 
ref 
mGST1        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.48 
ref 
p=0.16 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
1411 vi     
1417 
1252 
1039 
907 
1.56 
1.56 
1.38 
1.15 
ref 
 -++- 
mGST2        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.03 
ref 
p=0.92 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
434 vi       
524 
425 
382 
458 
0.95 
1.14 
0.93 
0.83 
ref 
 -++- 
Thioredoxin Metabolism 
TXN        
TXN1        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.39 
ref 
p=0.07 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
2259 vi     
2586 
1966 
1474 
1069 
2.11 
2.42 
1.84 
1.38 
ref 
 -++- 
TXN2        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
274 vi      
296 
278 
0.95 
1.02 
0.96 
 -++- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
Asymptomatic smokers (18) 
Nonsmokers (18) 
260 
289 
0.90 
ref 
TXNRD        
TXNRD1        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 2.20 
ref 
p=0.0007 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
1650 vi     
1879 
1564 
1443 
853 
1.93 
2.20 
1.83 
1.69 
ref 
 -++- 
TXNRD2        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
114 vi      
116 
117 
111 
114 
1.00 
1.02 
1.03 
0.97 
ref 
 -++- 
TXNRD3        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
133 vi       
135 
132 
131 
130 
1.02 
1.04 
1.02 
1.01 
ref 
 -++- 
PRDX        
PRDX1        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
5786 vi     
6883 
5558 
4923 
3845 
1.50 
1.79 
1.45 
1.28 
ref 
 -++- 
PRDX2        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
329 
375 
452 vi 
483 
1.13 
1.28 
0.95 
1.02 
 -++- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
313 
287 
292 
446 
467 
474 
1.07 
0.98 
ref 
0.94 
0.99 
ref 
PRDX3        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
703 vi       
1067 
625 
584 
784 
0.90 
1.36 
0.80 
0.74 
ref 
 -++- 
PRDX4        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.16 
ref 
p=0.55 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
551 vi       
670 
517 
448 
452 
1.22 
1.48 
1.14 
0.99 
ref 
 -++- 
PRDX5        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
1798 vi     
1751 
1940 
1940 
2543 
0.71 
0.69 
0.76 
0.76 
ref 
 -++- 
PRDX6        
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
1029 vi      
1243 
998 
1024 
1111 
0.93 
1.12 
0.90 
0.92 
ref 
 -++- 
Other Antioxidant Enzymes  
TABLE A.4 (continued) 
 
 
 
125
Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
SOD        
SOD        
Yigla 
2007 
Bronchoalveolar 
lavage fluid 
Enzyme 
Assay 
COPD patients (smokers) (10) 
COPD patients (nonsmokers) (10) 
Asymptomatic smokers (10) 
Nonsmokers without COPD (10) 
1.25 ± 0.31 
2.00 ± 0.80 
0.98 ± 0.12 
1.07 ± 0.16 
1.17 
1.87 
0.92 
ref 
NS 
NS 
NS 
-+00 
SOD1        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.26 
ref 
p=0.28 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
2446 vi     
2946 
1996 
2030 
2277 
1.07 
1.29 
0.88 
0.89 
ref 
 -++- 
Harju 
2004 
Lung tissue 
homogenate v 
Western blot Smokers (with moderate to no 
COPD) (4) 
Lifelong nonsmokers (3) 
 1.25 
ref 
NS -+0- 
Tomaki 
2007 
Peripheral lung tissue 
(lung resection) v 
 
RT-PCR COPD patients (smokers) (14) 
Smokers (9) 
Nonsmokers (10) 
0.045 ± 0.007 
0.047 ± 0.010 
0.058 ± 0.008 
0.78 
0.81 
ref 
NS 
NS 
-++- 
Kondo 
1994 
Alveolar 
Macrophages 
(bronchoalveolar 
lavage) 
Northern blot Asymptomatic elderly male 
smokers (3) 
Asymptomatic elderly male 
nonsmokers (3) 
No 
differenceviii 
1.0 
ref 
 ++00 
SOD2        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 0.8 
ref 
p=0.3 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
153 
84 
130 
85 
138 vi 
104 
114 
98 
1.38 
0.76 
1.17 
0.77 
0.91 
0.68 
0.75 
0.64 
 -++- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
Nonsmokers (18) 111 152 ref ref 
Harju 
2004 
Central bronchus 
epithelium v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
1.8 ± 0.2 GR 
1.4 ± 0.2 
0.9 ± 0.2 
2.0 
1.6 
ref 
p=0.041 
NS 
-+0- 
Harju 
2004 
Bronchioli epithelium 
v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
0.5 ± 0.2 GR 
0.3 ± 0.1 
0.4 ± 0.2 
1.25 
0.75 
ref 
NS 
NS 
-+0- 
Harju 
2004 
Alveolar epithelium v Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
0.6 ± 0.2 GR 
0.5 ± 0.1 
0.05 ± 0.08 
12.0 
10.0 
ref 
p=0.01 
p=0.022 
-+0- 
Harju 
2004 
Lung tissue 
homogenate v 
Western blot Smokers (moderate/no COPD) (4) 
Lifelong nonsmokers (3) 
 1.33vi
ref 
 -+0- 
Tomaki 
2007 
Peripheral lung tissue 
(lung resection) v 
 
RT-PCR COPD patients (smokers) (14) 
Smokers (9) 
Nonsmokers (10) 
0.660 ± 0.139 
0.517 ± 0.122 
0.384 ± 0.090 
1.72 
1.35 
ref 
NS 
NS 
-++- 
Harju 
2004 
Alveolar 
macrophages v 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
1.8 ± 0.2 GR 
1.7 ± 0.1 
1.1 ± 0.3 
1.6 
1.5 
ref 
NS 
NS 
-+0- 
Harju 
2004 
Pulmonary blood 
vessels v 
 
Immunohistoc
hemistry 
COPD patients (smokers) (22)  
Asymptomatic smokers (20) 
Asymptomatic nonsmokers (13) 
0.03 ± 0.04 
GR 
0.04 ± 0.03 
0.07 ± 0.07 
0.4 
0.6 
ref 
NS 
NS 
-+0- 
SOD3        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.17 
ref 
p=0.52 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
174 vi       
158 
171 
169 
161 
1.08 
0.98 
1.06 
1.05 
ref 
 -++- 
Harju 
2004 
Lung tissue 
homogenate v 
Western blot Smokers (moderate/no COPD) (4) 
Lifelong nonsmokers (3) 
 1.21vi
ref 
 -+0- 
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Reference Tissue i 
(Collection method) 
Assay Subgroups ii (n) Mean ± SEM Ratio iii T Test  Quality Score 
(PEOC)iv 
Tomaki 
2007 
Peripheral lung tissue 
(lung resection) v 
 
RT-PCR COPD patients (smokers) (14) 
Smokers (9) 
Nonsmokers (10) 
0.187 ± 0.013 
0.234 ± 0.013 
0.221 ± 0.018 
0.85 
1.06 
ref 
NS 
NS 
-++- 
CAT        
Hackett 
2003  
Airway epithelial 
cells (bronchoscopy) 
Microarray Asymptomatic smokers (13) 
Asymptomatic nonsmokers (9) 
 1.36 
ref 
p=0.27 ++++ 
Pierrou 
2007 
Bronchial epithelial 
cells (bronchoscopy) 
Microarray COPD patients, stage 0 (18)  
COPD patients, stage 1 (7) 
COPD patients, stage 2-4 (13) 
Asymptomatic smokers (18) 
Nonsmokers (18) 
399 
487 
439 
388 
504 
1331 vi 
1992 
1409 
1412 
1463 
0.67 
0.97 
0.87 
0.77 
ref 
0.91 
1.36 
0.96 
0.97 
ref 
 -++- 
Tomaki 
2007 
Peripheral lung tissue 
(lung resection) v 
 
RT-PCR COPD patients (smokers) (14) 
Smokers (9) 
Nonsmokers (10) 
0.165 ± 0.013 
0.233 ± 0.026 
0.251 ± 0.025 
0.66 
0.93 
ref 
p<0.01 
NS 
-++- 
i Lung tissue sample unless otherwise indicated 
ii Reference group for all comparisons is the last subgroup listed: the ratios and significance tests listed are for the subgroup compared to the reference group. 
iii Ratio of subgroup to reference group (last group listed) 
iv Quality scores (+,0,-) given for the following categories in this order: Population Selection, Exposure Status, Outcome Determination, and Covariate Handling. 
v All study participants undergoing lung resection for tumor (non-tumor tissue tested) 
vi Median values reported, so t-test could not be performed.  When multiple probe sets gave similar patterns of regulation, the average is listed.  When multiple probe 
sets gave different patterns, they are listed separately in divided column. 
vii Comparison group for this result is asymptomatic smokers 
viii No quantitative data given for this result 
GR Semi-quantitative grading of stain intensity 
RCE Ratio with a control enzyme
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Gene Name (Abbreviation) 
Functional 
Group 
Gene 
Length 
(kb) 
LDU across 
Gene 
SNPs 
NS 
SNPs 
Af 
Amer 
Eur 
Amer 
Catalase (CAT) Catalase 33 1.16 0.06 7 0 
Gamma-glutamyl Transferase 
1 (GGT1) 
GSH 
Synthesis 
45 2.05 1.83 3 0 
Glucose-6-Phosphate 
Dehydrogenase (G6PD) 
Reducing 
Equivalents 
16 0 0 1 0 
Glutamate-cysteine ligase 
(catalytic) (GCLC) 
GSH 
Synthesis 
48 3.85 1.71 15 0 
Glutamate-cysteine ligase 
(modulatory) (GCLM) 
GSH 
Synthesis 
22 0.16 0.18 6 0 
Glutaredoxin (GLRX) Disulfide 
Reductase 
9 0.74 0.21 5 0 
Glutaredoxin 2 (GLRX2) Disulfide 
Reductase 
10 0 0 6 0 
Glutathione Peroxidase 1 
(GPX1) 
Peroxidase 
Activity 
1.2 0.02 0 3 0 
Glutathione Peroxidase 2 
(GPX2) 
Peroxidase 
Activity 
3.7 0.12 0 5 0 
Glutathione Peroxidase 3 
(GPX3) 
Peroxidase 
Activity 
8.5 1.11 0.45 4 0 
Glutathione Peroxidase 4 
(GPX4) 
Peroxidase 
Activity 
2.9 0.78 0.14 5 0 
Glutathione Peroxidase 7 
(GPX7) 
Peroxidase 
Activity 
6.7 0 0 5 0 
Glutathione Reductase (GSR) Disulfide 
Reductase 
49 1.96 0.10 9 1 
Glutathione S-Transferase A1 
(GSTA1) 
Glutathione S-
Transferase 
12 0.01 0 3 0 
Glutathione S-Transferase A2 
(GSTA2) 
Glutathione S-
Transferase 
13 1.19 0.19 3 1 
Glutathione S-Transferase A3 
(GSTA3) 
Glutathione S-
Transferase 
13 0 0.03 6 1 
Glutathione S-Transferase A4 
(GSTA4) 
Glutathione S-
Transferase 
17 0 0.48 6 0 
Glutathione S-Transferase A5 
(GSTA5) 
Glutathione S-
Transferase 
14 0.18 0 7 1 
Glutathione S-Transferase K1 
(GSTK1) 
Glutathione S-
Transferase 
5.6 0.15 0.01 1 0 
Glutathione S-Transferase M2 
(GSTM2) 
Glutathione S-
Transferase 
7.2 0 0.55 3 0 
Glutathione S-Transferase M3 
(GSTM3) 
Glutathione S-
Transferase 
6.5 0.283 0.089 6 1 
Glutathione S-Transferase M4 
(GSTM4) 
Glutathione S-
Transferase 
9.4 0.235 0.664 4 0 
Glutathione S-Transferase O1 
(GSTO1) 
Glutathione S-
Transferase 
13 0 0.005 4 0 
Glutathione S-Transferase O2 
(GSTO2) 
Glutathione S-
Transferase 
31 0.863 0.082 9 1 
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Gene Name (Abbreviation) 
Functional 
Group 
Gene 
Length 
(kb) 
LDU across 
Gene 
NS 
SNPs SNPs 
Af 
Amer 
Eur 
Amer 
Glutathione S-Transferase P1 
(GSTP1) 
Glutathione S-
Transferase 
2.8 0.055 0.083 8 2 
Glutathione S-Transferase Z1 
(GSTZ1) 
Glutathione S-
Transferase 
8.1 0 0 6 2 
Glutathione Synthetase (GSS) GSH 
Synthesis 
11 0.199 0.147 7 0 
Heme-Oxygenase 1 (HMOX1) Heme-
Oxygenase 
13 0.234 0.206 5 0 
Heme-Oxygenase 2 (HMOX2) Heme-
Oxygenase 
34 0 0.099 6 0 
Isocitrate Dehydrogenase 1 
(IDH1) 
Reducing 
Equivalents 
19 1.188 0.443 7 1 
Isocitrate Dehydrogenase 2 
(IDH2) 
Reducing 
Equivalents 
19 0.849 2.134 7 0 
Isocitrate Dehydrogenase 3A 
(IDH3A) 
Reducing 
Equivalents 
21 0 0.192 5 0 
Isocitrate Dehydrogenase 3B 
(IDH3B) 
Reducing 
Equivalents 
5.8 0.571 0.116 4 0 
Isocitrate Dehydrogenase 3G 
(IDH3G) 
Reducing 
Equivalents 
8.7 0 0.236 5 0 
Microsomal Glutathione S-
Transferase 1 (mGST1) 
Glutathione S-
Transferase 
17 1.151 2.013 8 0 
Microsomal Glutathione S-
Transferase 2 (mGST2) 
Glutathione S-
Transferase 
39 8.838 1.303 11 0 
Microsomal Glutathione S-
Transferase 3 (mGST3) 
Glutathione S-
Transferase 
24 3.25 1.293 11 0 
Peroxiredoxin 1 (PRDX1) Peroxidase 
Activity 
11 0 0 3 0 
Peroxiredoxin 2 (PRDX2) Peroxidase 
Activity 
5 0.005 0 6 0 
Peroxiredoxin 3 (PRDX3) Peroxidase 
Activity 
11 0.271 0.107 6 0 
Peroxiredoxin 4 (PRDX4) Peroxidase 
Activity 
19 0.218 0.039 6 0 
Peroxiredoxin 5 (PRDX5) Peroxidase 
Activity 
3.7 0.145 0 6 1 
Peroxiredoxin 6 (PRDX6) Peroxidase 
Activity 
11 0.005 0 6 0 
Selenoprotein P 1 (SEPP1) Selenoprotein 12 0.154 0.312 6 1 
Selenoprotein W 1 (SEPW1) Selenoprotein 6.1 0.032 0.131 7 0 
Superoxide Dismutase 1 
(SOD1) 
Superoxide 
Dismutase 
9.3 0 0 6 0 
Superoxide Dismutase 2 
(SOD2) 
Superoxide 
Dismutase 
14 0.074 0.143 6 1 
Superoxide Dismutase 3 
(SOD3) 
Superoxide 
Dismutase 
6.4 2.603 2.277 10 1 
Thioredoxin 1 (TXN) Thioredoxin 12 1.524 1.078 5 0 
Thioredoxin 2 (TXN2) Thioredoxin 15 1.031 0.308 5 0 
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Gene Name (Abbreviation) 
Functional 
Group 
Gene 
Length 
(kb) 
LDU across 
Gene 
NS 
SNPs SNPs 
Af 
Amer 
Eur 
Amer 
Thioredoxin Reductase 1 
(TXNRD1) 
Disulfide 
Reductase 
63 0 0 8 0 
Thioredoxin Reductase 2 
(TXNRD2) 
Disulfide 
Reductase 
66 3.599 3.071 12 1 
Thioredoxin Reductase 3 
(TXNRD3) 
Disulfide 
Reductase 
52 0.892 0.356 4 0 
 
*Abbreviations: African American (Af Amer), European American (Eur Amer), Linkage 
Disequilibrium Units (LDU), Nonsynonymous (NS), Single nucleotide polymorphisms  
(SNPs)
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Gene Single 
Nucleotide 
Polymorphism 
Minor Allele Frequency Type 
European 
Americans 
African 
Americans 
Catalase rs564250 22% 20% 5’ region 
 rs769214 33% 41% 5’ region 
 rs484214 29% 29% Intron 
 rs7933285 27% 18% Intron 
 rs769217 23% 16% Intron 
 rs2420388 23% 18% Intron 
 rs475043 38% 10% 3’ region 
Glucose-6-Phosphate                      rs2472394 10% 13% Intron 
             Dehydrogenase     
Glutamate-cysteine ligase  rs742528 26% 38% 3’ region 
             (catalytic subunit) rs6458939 25% 42% 3’ region 
 rs7742367 19% 31% 3’ region 
 rs2066511 26% 25% Intron 
 rs16883894 9% 35% Intron 
 rs1555903 9% 27% Intron 
 rs622447 20% 17% Intron 
 rs600033 45% 36% Intron 
 rs4715407 8% 25% Intron 
 rs4712035 19% 34% Intron 
 rs2397147 37% 24% Intron 
 rs606548 6% 34% Intron 
 rs2284650 5% 6% Intron 
 rs510088 31% 18% Intron 
 rs17883901 8% 3% 5’ region 
Glutamate-cysteine ligase  rs7549683 35% 36% 3’ region 
             (modulatory subunit) rs769211 26% 24% Intron 
 rs7517826 35% 36% Intron 
 rs3827715 26% 25% Intron 
 rs2301022 31% 47% Intron 
 rs41303970 18% 19% 5’ region 
Gamma-glutamyl Transferase 1 rs16978740 3% 10% Intron 
 rs2154611 28% 32% Intron 
 rs6519519 26% 39% Intron 
Glutaredoxin rs1047420 38% 15% 3’ region 
 rs4561 41% 32% Synonymous 
 rs3822751 25% 47% Intron 
 rs9314160 43% 42% Intron 
 rs3756704 47% 32% 5’ region 
Glutaredoxin 2 rs34552619 0% 8% 3’ region 
 rs35358794 1% 6% Intron 
 rs4657845 26% 25% Intron 
 rs10801174 32% 48% Intron 
 rs912071 27% 27% 5’ region 
 rs7547615 32% 48% 5’ region 
Glutathione Peroxidase 1 rs8179172 0% 9% 3’ region 
 rs3811699 33% 29% 5’ region 
 rs3448 25% 27% 5’ region 
Glutathione Peroxidase 2 rs10133054 22% 42% 3’ region 
 rs4902346 22% 41% Intron 
 rs2412065 22% 41% Intron 
 rs2737844 31% 21% Intron 
 rs17102360 7% 10% 5’ region 
Glutathione Peroxidase 3 rs1946234 14% 20% 5’ region 
 rs3828599 25% 43% Intron 
 rs8177435 39% 30% Intron 
 rs8177447 17% 33% Intron 
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Gene Minor Allele FrequencySingle 
Nucleotide 
Polymorphism 
 Type 
European 
Americans 
African 
Americans 
Glutathione Peroxidase 4 rs757228 45% 41% 5’ region 
 rs3746165 45% 42% 5’ region 
 rs4807542 18% 4% Synonymous 
 rs8178977 23% 30% Intron 
 rs2074451 50% 29% 3’ region 
Glutathione Peroxidase 7 rs6588431 39% 40% 5’ region 
 rs3753753 26% 13% Intron 
 rs946154 33% 41% Intron 
 rs1047635 45% 38% 3’ region 
 rs7529595 31% 12% 3’ region 
Glutathione Reductase rs3594 39% 18% 3’ region 
 rs2250192 21% 35% Intron 
 rs8190996 43% 32% Intron 
 rs8190955 0% 8% Nonsynonymous 
 rs2978662 19% 34% Intron 
 rs2978296 19% 29% Intron 
 rs10088455 0% 35% Intron 
 rs8190907 0% 38% Intron 
 rs1002149 17% 24% 5’ region 
Glutathione Synthetase rs725521 39% 46% 3’ region 
 rs6087651 39% 45% Intron 
 rs6087653 39% 46% Intron 
 rs2273684 45% 30% Intron 
 rs6060127 29% 20% Intron 
 rs6088659 19% 4% Intron 
 rs3761144 41% 24% 5’ region 
Glutathione S-Transferase A1 rs6920039 0% 9% 3’ region 
 rs6917325 44% 31% Intron 
 rs3756982 44% 31% 5’ region 
Glutathione S-Transferase A2 rs2180314 43% 33% Nonsynonymous 
 rs2180319 33% 7% Intron 
 rs2608629 37% 14% Intron 
Glutathione S-Transferase A3 rs10214816 3% 18% 3’ region 
 rs557135 37% 35% Intron 
 rs1052661 0% 13% Nonsynonymous 
 rs2281594 4% 40% Intron 
 rs614765 4% 43% Intron 
 rs563464 3% 33% 5’ region 
Glutathione S-Transferase A4 rs405729 45% 45% 3’ region 
 rs316133 39% 48% Intron 
 rs3756980 20% 11% Intron 
 rs6904771 2% 24% Intron 
 rs11967816 8% 7% Intron 
 rs13207376 8% 10% Intron 
Glutathione S-Transferase A5 rs4236107 0% 15% 3’ region 
 rs10948726 40% 9% 3’ region 
 rs7755335 4% 13% Intron 
 rs2397118 4% 13% Nonsynonymous 
 rs4715353 44% 38% Intron 
 rs4715354 46% 16% Intron 
 rs7749576 6% 42% Intron 
Glutathione S-Transferase K1 rs7803893 0% 4% Intron 
Glutathione S-Transferase M2 rs638820 48% 50% 5’ region 
 rs625456 14% 17% Intron 
 rs673151 6% 3% Intron 
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Gene Minor Allele FrequencySingle 
Nucleotide 
Polymorphism 
 Type 
European 
Americans 
African 
Americans 
Glutathione S-Transferase M3 rs1927328 31% 12% 3’ region 
 rs1537236 49% 41% 3’ region 
 rs7483 30% 12% Nonsynonymous 
 rs1571858 30% 15% Intron 
 rs10735234 43% 16% Intron 
 rs1332018 44% 19% 5’ region 
Glutathione S-Transferase M4 rs560018 36% 14% Intron 
 rs535537 13% 12% Intron 
 rs627365 14% 3% Intron 
 rs670439 14% 13% Intron 
Glutathione S-Transferase O1 rs2164624 34% 13% 5’ region 
 rs12259337 0% 25% Intron 
 rs17116741 0% 25% Intron 
 rs1147611 38% 28% Intron 
Glutathione S-Transferase O2 rs12264844 0% 25% 5’ region 
 rs7089730 0% 25% Intron 
 rs7070750 0% 34% Intron 
 rs157077 46% 25% Intron 
 rs156697 35% 29% Nonsynonymous 
 rs276203 35% 29% Intron 
 rs157076 32% 33% Intron 
 rs157080 32% 31% Intron 
 rs3740466 29% 24% 3’ region 
Glutathione S-Transferase P1 rs6591256 39% 38% 5’ region 
 rs4147581 49% 16% Intron 
 rs8191446 0% 12% Intron 
 rs1695 32% 45% Nonsynonymous 
 rs749174 33% 26% Intron 
 rs743679 0% 12% Intron 
 rs1138272 8% 1% Nonsynonymous 
 rs947895 33% 26% 3’ region 
Glutathione S-Transferase Z1 rs2111699 32% 31% Intron 
 rs2363643 32% 31% Splice Site 
Donor 
 rs2270422 39% 15% Intron 
 rs3177427 34% 29% Nonsynonymous 
 rs1046428 20% 9% Nonsynonymous 
 rs1017186 20% 11% 3’ region 
Heme-Oxygenase 1 rs6518952 0% 32% Intron 
 rs2071749 46% 12% Intron 
 rs5755720 35% 20% Intron 
 rs2285112 41% 34% Intron 
 rs17883419 6% 11% 3’ region 
Heme-Oxygenase 2 rs11639998 26% 22% Intron 
 rs8055559 4% 26% Intron 
 rs11643057 28% 35% Intron 
 rs1362626 27% 48% Intron 
 rs2270366 32% 25% Intron 
 rs1051308 31% 25% 3’ region 
Isocitrate Dehydrogenase 1 rs7593466 21% 35% 3’ region 
 rs7565247 8% 42% Intron 
 rs34218846 7% 8% Nonsynonymous 
 rs6435435 7% 13% Intron 
 rs12612631 0% 14% Intron 
 rs1437410 42% 22% Intron 
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Gene Minor Allele FrequencySingle 
Nucleotide 
Polymorphism 
 Type 
European 
Americans 
African 
Americans 
 rs10207062 42% 22% 5’ region 
Isocitrate Dehydrogenase 2 rs7176347 0% 12% 3’ region 
 rs9972549 2% 43% Intron 
 rs11073899 17% 20% Intron 
 rs8030346 41% 28% Intron 
 rs8028234 25% 35% Intron 
 rs4932279 44% 24% Intron 
 rs7182369 25% 34% Intron 
Isocitrate Dehydrogenase 3A rs11631100 42% 47% Intron 
 rs8032618 50% 33% Intron 
 rs7180781 1% 11% Intron 
 rs3816253 44% 48% Intron 
 rs17674205 8% 2% 3’ region 
Isocitrate Dehydrogenase 3B rs6037255 26% 41% Intron 
 rs6115381 7% 37% Intron 
 rs6107100 7% 37% Intron 
 rs2073192 7% 5% 5’ region 
Isocitrate Dehydrogenase 3G rs2071122 28% 35% Intron 
 rs2071123 28% 34% Intron 
 rs2071124 7% 10% Intron 
 rs17429 0% 22% Intron 
 rs2283753 7% 10% Intron 
 rs4898445 35% 26% Intron 
Microsomal Glutathione  rs7970208 47% 29% 5’ region 
            S-Transferase 1 rs7294985 24% 36% Intron 
 rs2975149 25% 42% Intron 
 rs2075237 20% 15% Intron 
 rs4149197 31% 46% Intron 
 rs9332939 50% 31% Intron 
 rs3852576 49% 22% Intron 
 rs7135371 49% 31% 3’ region 
Microsomal Glutathione  rs8191997 16% 26% 5’ region 
            S-Transferase 2 rs8192004 9% 6% 5’ region 
 rs1000222 39% 48% Intron 
 rs795594 47% 23% Intron 
 rs8192047 26% 9% Intron 
 rs795590 2% 9% Intron 
 rs795589 42% 49% Intron 
 rs8192066 0% 7% Intron 
 rs7664313 21% 39% Intron 
 rs2646076 22% 28% Intron 
 rs2646035 17% 42% 3’ region 
Microsomal Glutathione  rs7549530 16% 19% 5’ region 
            S-Transferase 3 rs10737515 47% 20% 5’ region 
 rs9333378 38% 36% Intron 
 rs10800120 40% 20% Intron 
 rs7554034 21% 46% Intron 
 rs957644 26% 46% Intron 
 rs9333471 29% 44% Intron 
 rs4147602 31% 43% Intron 
 rs2297765 44% 36% Intron 
 rs7533986 30% 26% Intron 
 rs10494446 14% 29% Intron 
Peroxiredoxin 1 rs4660306 35% 19% Intron 
 rs2152077 35% 41% Intron 
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Gene Minor Allele FrequencySingle 
Nucleotide 
Polymorphism 
 Type 
European 
Americans 
African 
Americans 
 rs713358 22% 25% 5’ region 
Peroxiredoxin 2 rs10404253 1% 23% 3’ region 
 rs35866106 1% 5% Intron 
 rs10413408 3% 18% Intron 
 rs1205171 18% 5% Intron 
 rs10422248 3% 16% Intron 
 rs8107906 3% 18% 5’ region 
Peroxiredoxin 3 rs7068937 47% 19% 3’ region 
 rs7768 33% 44% 3’ region 
 rs11198808 13% 16% Intron 
 rs4752257 13% 19% Intron 
 rs11198811 32% 48% Intron 
 rs1553850 42% 23% 5’ region 
Peroxiredoxin 4 rs557914 40% 37% Intron 
 rs513573 40% 38% Intron 
 rs528960 9% 24% Intron 
 rs518329 40% 38% Intron 
 rs795489 42% 32% Intron 
 rs1548734 40% 38% Intron 
 rs477233 42% 41% 3’ region 
Peroxiredoxin 5 rs9787810 32% 7% 5’ region 
 rs7938623 0% 19% Nonsynonymous 
 rs7941847 0% 12% Intron 
 rs566049 0% 13% Intron 
 rs1047206 15% 5% 3’ region 
 rs4930702 14% 25% 3’ region 
Peroxiredoxin 6 rs34619706 10% 2% 5’ region 
 rs34977864 0% 7% 5’ region 
 rs7540065 25% 38% Intron 
 rs9425725 0% 20% Intron 
 rs34308867 0% 10% Intron 
 rs6702835 24% 41% 3’ region 
Selenoprotein P 1 rs230813 46% 45% 3’ region 
 rs6413428 25% 34% 3’ region 
 rs3877899 24% 27% Nonsynonymous 
 rs1046068 29% 15% Intron 
 rs230820 45% 45% Intron 
 rs6865453 26% 7% Intron 
Selenoprotein W 1 rs11670990 33% 43% 5’ region 
 rs1862485 31% 25% Intron 
 rs3815751 33% 46% Intron 
 rs10412896 36% 42% Intron 
 rs10427074 0% 12% Intron 
 rs3786777 48% 11% Intron 
 rs2042286 42% 42% 3’ region 
Superoxide Dismutase 1 rs11910115 0% 12% 5’ region 
 rs4998557 11% 39% Intron 
 rs2070424 6% 19% Intron 
 rs1041740 32% 10% Intron 
Superoxide Dismutase 2 rs4342445 22% 15% 3’ region 
 rs2758329 50% 41% 3’ region 
 rs8031 49% 34% Intron 
 rs2758331 49% 25% Intron 
 rs4880 48% 44% Nonsynonymous 
 rs2758346 49% 44% 5’ region 
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Gene Minor Allele FrequencySingle 
Nucleotide 
Polymorphism 
 Type 
European 
Americans 
African 
Americans 
Superoxide Dismutase 3 rs2284659 37% 18% 5’ region 
 rs8192287 7% 2% 5’ region 
 rs699474 2% 9% Intron 
 rs17885542 1% 13% Intron 
 rs17878863 8% 1% Intron 
 rs7655372 1% 8% Intron 
 rs1007991 34% 22% Intron 
 rs1799895 1% 0% Nonsynonymous 
 rs2855262 37% 18% 3’ region 
 rs2695234 9% 50% 3’ region 
Thioredoxin 1 rs2026312 42% 35% 3’ region 
 rs1964889 34% 25% Intron 
 rs2418076 27% 44% Intron 
 rs4135191 2% 10% Intron 
 rs4135168 25% 28% Intron 
Thioredoxin 2 rs5995291 11% 34% Intron 
 rs8139906 18% 40% Intron 
 rs2283965 19% 24% Intron 
 rs2267337 19% 22% Intron 
 rs2281082 20% 22% Intron 
Thioredoxin Reductase 1 rs11111979 46% 32% 5’ region 
 rs4523760 24% 26% Intron 
 rs5018287 46% 37% Intron 
 rs4595619 46% 32% Intron 
 rs17202060 34% 17% Intron 
 rs7138318 32% 39% Intron 
 rs11610799 8% 13% Intron 
 rs4964785 46% 38% 3’ region 
Thioredoxin Reductase 2 rs7285948 16% 38% 3’ region 
 rs1139795 17% 45% Synonymous 
 rs1139793 26% 10% Nonsynonymous 
 rs2073750 23% 44% Intron 
 rs9606173 15% 18% Intron 
 rs5992493 18% 50% Intron 
 rs3788314 48% 28% Intron 
 rs756661 44% 25% Intron 
 rs5748469 36% 24% Nonsynonymous 
 rs5748471 44% 23% Intron 
 rs9306229 22% 15% Intron 
 rs737866 29% 14% 5’ region 
Thioredoxin Reductase 3 rs9834240 35% 38% Intron 
 rs1520850 34% 46% Intron 
 rs777238 12% 50% Intron 
 rs9637365 42% 27% Intron 
 
 
 
 
TABLE A.8 
Most statistically significant SNPs in models with small numbers in genotype/smoking subgroupsa 
Population Outcome SNP*smoking parameterb Gene Function P-valuec 
European ppFEV1 rs38778993*Status SEPP1 Selenoprotein 0.001 
Americans  Rs34619706*Dose PRDX6 Peroxidase Activity 0.001 
 FEV1/FVC Rs2154611*Statusd GGT1 GSH Synthesis 0.001 
  Rs6519519*Statusd GGT1 GSH Synthesis 0.001 
  Rs8177447*Status GPX3 Peroxidase Activity 0.002 
  Rs2154611*Dosed GGT1 GSH Synthesis 0.0002 
  Rs6519519*Dosed GGT1 GSH Synthesis 0.0002 
  Rs17102360*Dose GPX2 Peroxidase Activity 0.002 
  Rs8177447*Dose GPX3 Peroxidase Activity 0.0002 
  Rs7749576*Dose GSTA5 Glutathione S-Transferase 0.0005 
  Rs1046428*Dosee GSTZ1 Glutathione S-Transferase 0.0002 
  Rs1017186*Dosee GSTZ1 Glutathione S-Transferase 0.0002 
  Rs795590*Dose mGST2 Glutathione S-Transferase 0.002 
  Rs4342445*Dose 
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SOD2 Superoxide Dismutase 0.002 
African ppFEV1 Rs699474*Dose SOD3 Superoxide Dismutase 0.002 
Americans FEV1/FVC Rs2284650*Status GCLC Glutathione Synthesis 0.000001 
  Rs2071749*Status HMOX1 Heme-Oxygenase 0.0004 
  Rs3786777*Status SEPW1 Selenoprotein 0.0006 
  Rs528960*Status PRDX4 Peroxidase Activity 0.002 
  Rs2042286*Status SEPW1  Selenoprotein 0.0002 
  Rs2284650*Dose GCLC Glutathione Synthesis 0.0000008 
  Rs2978296*Dose GSR Disulfide Reductase 0.001 
  Rs563464*Dose GSTA3 Glutathione S-Transferase 0.00001 
  Rs2071749*Dose HMOX1 Heme-Oxygenase 0.001 
  Rs7176347*Dose IDH2 Reducing Equivalents 0.0009 
aAll results with nominal p-value <0.002 
bSNPs (single nucleotide polymorphisms) in bold remained statistically significant after adjustment for multiple comparisons 
cNominal p-values shown 
dStrong LD observed between these SNPs (R2=0.93) 
eStrong LD observed between these SNPs (R2=0.90) 
 
 
